GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Sirolimus

Company
National Human Genome Research Institute (NHGRI)
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
29 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

29 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Sirolimus and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT03121001

    Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

    Not yet reported University of Illinois at Chicago 50 participants Est. completion 2029-05 1 site Stand-alone
    Other conditions: Sickle Cell Disease
    View official trial listing →
  • Recruiting NCT NCT03587272

    Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

    Not yet reported Robert Nickel 100 participants Est. completion 2030-11 7 sites Stand-alone
    Other conditions: Sickle Cell Disease
    View official trial listing →
  • Recruiting NCT NCT03952637

    A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

    Not yet reported, Not yet reported National Human Genome Research Institute (NHGRI) 54 participants Est. completion 2030-01-01 1 site Stand-alone
    Other conditions: Lysosomal Diseases, Gangliosidosis, GM1
    View official trial listing →
  • Recruiting NCT NCT03970096

    Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

    Not yet reported Fred Hutchinson Cancer Center 120 participants Est. completion 2029-12-31 3 sites Stand-alone
    Other conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
    View official trial listing →
  • Recruiting NCT NCT04022616

    Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

    Ohio State University Comprehensive Cancer Center 99 participants Est. completion 2027-12-31 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04936854

    Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease

    Not yet reported Haukeland University Hospital 60 participants Est. completion 2028-12 1 site
    Other conditions: Thyroid-Associated Ophthalmopathy
    View official trial listing →
  • Recruiting NCT NCT05036226

    COAST Therapy in Advanced Solid Tumors and Prostate Cancer

    Not yet reported, Not yet reported Medical University of South Carolina 76 participants Est. completion 2028-05-21 1 site Stand-alone
    Other conditions: Prostate Cancer Recurrent, Solid Tumor, Adult
    View official trial listing →
  • Recruiting NCT NCT05237687

    The Role of Sirolimus in Preventing Functional Decline in Older Adults

    Not yet reported Irina Timofte 10 participants Est. completion 2028-01 1 site Stand-alone
    Other conditions: Aging
    View official trial listing →
  • Recruiting NCT NCT05508906

    Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

    Not yet reported Olema Pharmaceuticals, Inc. 190 participants Est. completion 2028-01-31 16 sites
    Other conditions: Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05549167

    Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA)

    Not yet reported Federal Research Institute of Pediatric Hematology, Oncology and Immunology 117 participants Est. completion 2029-12-30 1 site Stand-alone
    Other conditions: Juvenile Nasopharyngeal Angiofibroma
    View official trial listing →
  • Recruiting NCT NCT05661461

    Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

    Not yet reported Aadi Bioscience, Inc. 28 participants Est. completion 2026-08-01 2 sites Stand-alone
    Other conditions: Tumor, Solid, Tumor, Advanced Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT05925023

    Sirolimus in the Treatment of Refractory/Relapsed wAIHA

    Not yet reported Peking Union Medical College Hospital 22 participants Est. completion 2025-12 1 site Stand-alone
    Other conditions: Warm Autoimmune Hemolytic Anemia
    View official trial listing →
  • Recruiting NCT NCT05933395

    Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

    Not yet reported Dartmouth-Hitchcock Medical Center 135 participants Est. completion 2031-10 1 site
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05949541

    Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer

    Not yet reported Fudan University 265 participants Est. completion 2028-01 1 site
    Other conditions: Breast Cancer, Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06075420

    Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease

    Genoss Co., Ltd. 1000 participants Est. completion 2027-12-31 1 site
    Other conditions: Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
    View official trial listing →
  • Recruiting NCT NCT06091332

    Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial

    Not yet reported Huashan Hospital 75 participants Est. completion 2026-12-31 2 sites Stand-alone
    Cardiovascular disease Other conditions: Cavernous Malformations, Intracerebral Hemorrhage
    View official trial listing →
  • Recruiting NCT NCT06236022

    The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus

    Not yet reported Tongji Hospital 276 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Dilated Cardiomyopathy, Kaposi's Sarcoma-Associated Herpesvirus Infection
    View official trial listing →
  • Recruiting NCT NCT06280950

    Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 340 participants Est. completion 2030-06-30 8 sites
    Other conditions: Liver Transplant
    View official trial listing →
  • Recruiting NCT NCT06310291

    VTP-1000 in Adults With Celiac Disease

    Not yet reported Barinthus Biotherapeutics 45 participants Est. completion 2026-11 16 sites
    Other conditions: Celiac Disease
    View official trial listing →
  • Recruiting NCT NCT06326190

    177Lu-DOTATATE for Recurrent Meningioma

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 136 participants Est. completion 2028-12-22 19 sites
    Other conditions: Recurrent Meningioma
    View official trial listing →
  • Recruiting NCT NCT06373601

    SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective

    Not yet reported Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS 140 participants Est. completion 2027-08-01 10 sites Stand-alone
    Cardiovascular disease Other conditions: Stenosis Coronary, Coronary Artery Lesion, Percutaneous Coronary Intervention
    View official trial listing →
  • Recruiting NCT NCT06618248

    Efficacy and Safety of Sirolimus-Coated Spiral Balloon for Coronary Bifurcation Lesions

    Not yet reported Dongguan TT Medical 280 participants Est. completion 2027-03 1 site Stand-alone
    Other conditions: Coronary Bifurcation Lesion
    View official trial listing →
  • Recruiting NCT NCT06822712

    Efficacy and Safety of Sirolimus-coated Coronary Balloon Dilatation Catheter for De Novo Coronary Bifurcation Lesions

    Not yet reported BrosMed Medical Co., Ltd 250 participants Est. completion 2026-06 1 site Stand-alone
    Other conditions: Coronary Arterial Disease (CAD)
    View official trial listing →
  • Recruiting NCT NCT06856200

    A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

    Not yet reported Fudan University 36 participants Est. completion 2026-06 1 site Stand-alone
    Other conditions: Advanced HR - Positive, HER2 - Negative Breast Cancer, Resistant to (Neo)Adjuvant Endocrine Therapy
    View official trial listing →
  • Recruiting NCT NCT06872333

    Allo HSCT for High Risk Hemoglobinopathies

    Not yet reported Masonic Cancer Center, University of Minnesota 62 participants Est. completion 2032-06-01 1 site Stand-alone
    Other conditions: Graft Failure, Sickle Cell Disease, Hemoglobinopathies
    View official trial listing →
  • Recruiting NCT NCT06950385

    Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

    Not yet reported Rapamycin Holdings Inc. 168 participants Est. completion 2031-01 29 sites
    Other conditions: Familial Adenomatous Polyposis (FAP)
    View official trial listing →
  • Recruiting NCT NCT07062965

    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

    Not yet reported Pfizer 400 participants Est. completion 2030-11-04 202 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07144150

    EVERO Drug-coated Balloon (DCB) Randomized Trial

    Not yet reported Cook Research Incorporated 410 participants Est. completion 2032-10 9 sites
    Other conditions: Peripheral Vascular Disease, Peripheral Arterial Disease
    View official trial listing →
  • Recruiting NCT NCT07542938

    Medeliver Intracranial Drug Coated Balloon Catheter for Symptomatic Intracranial Atherosclerotic Stenosis

    Not yet reported Xuanwu Hospital, Beijing 264 participants Est. completion 2027-11-30 15 sites Stand-alone
    Other conditions: Symptomatic Intracranial Atherosclerotic Stenosis
    View official trial listing →
  • Withdrawn NCT NCT00002790

    Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center
    Other conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Terminated NCT NCT00023244

    Steroid Withdrawal in Pediatric Kidney Transplant Recipients

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 274 participants Est. completion 2005-06 19 sites Stand-alone
    Other conditions: End-Stage Renal Disease
    View official trial listing →
  • Completed NCT NCT00028028

    CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 80 participants 1 site
    Other conditions: Extensive Stage Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00037531

    Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients

    Not yet reported Wyeth is now a wholly owned subsidiary of Pfizer 769 participants Est. completion 2004-08 20 sites
    Other conditions: Graft vs Host Disease, Kidney Transplantation
    View official trial listing →
  • Active, not recruiting NCT NCT00061568

    Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

    Not yet reported, Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 130 participants Est. completion 2028-01-20 1 site Stand-alone
    Other conditions: Congenital Hemolytic Anemia, Sickle Cell Disease
    View official trial listing →
  • Completed NCT NCT00065468

    Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma

    Not yet reported Pfizer 626 participants Est. completion 2011-03 153 sites
    Other conditions: Carcinoma, Renal Cell, Kidney Neoplasms
    View official trial listing →
  • Completed NCT NCT00071968

    Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse

    Not yet reported Jonsson Comprehensive Cancer Center 15 participants 1 site
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00072176

    Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

    Not yet reported National Cancer Institute (NCI) 62 participants Est. completion 2009-08 1 site
    Other conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma, Stage IIIA Endometrial Carcinoma, Stage IIIB Endometrial Carcinoma, Stage IIIC Endometrial Carcinoma, Stage IVA Endometrial Carcinoma, Stage IVB Endometrial Carcinoma
    View official trial listing →
  • Completed NCT NCT00078689

    Daclizumab and Sirolimus to Treat Uveitis

    Not yet reported National Eye Institute (NEI) 6 participants Est. completion 2008-07-18 1 site
    Other conditions: Uveitis
    View official trial listing →
  • Completed NCT NCT00085566

    Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 61 participants Est. completion 2008-02 2 sites
    Other conditions: Brain and Central Nervous System Tumors, Prostate Cancer
    View official trial listing →
  • Terminated NCT NCT00086346

    Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients

    Not yet reported Wyeth is now a wholly owned subsidiary of Pfizer 607 participants Est. completion 2008-07 42 sites
    Other conditions: Liver Transplantation
    View official trial listing →
  • Terminated NCT NCT00086840

    CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

    Not yet reported National Cancer Institute (NCI) 60 participants 1 site
    Other conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00087685

    RAD001 in Recurrent Endometrial Cancer Patients

    Not yet reported M.D. Anderson Cancer Center 35 participants Est. completion 2015-01 1 site
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT00092222

    Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

    Not yet reported National Cancer Institute (NCI) 75 participants Est. completion 2026-10-01 1 site
    Other conditions: Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
    View official trial listing →
  • Completed NCT NCT00093080

    Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

    Not yet reported Merck Sharp & Dohme LLC 216 participants Est. completion 2008-11
    Obstructive sleep apnea Other conditions: Sarcoma, Soft Tissue, Metastases
    View official trial listing →
  • Withdrawn NCT NCT00098462

    Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    Not yet reported, Not yet reported Jonsson Comprehensive Cancer Center
    Other conditions: Lung Cancer
    View official trial listing →
  • Terminated NCT NCT00101088

    Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

    Not yet reported National Cancer Institute (NCI) 21 participants 1 site
    Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia
    View official trial listing →
  • Completed NCT NCT00106353

    Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors

    Not yet reported, Not yet reported Pfizer 71 participants Est. completion 2012-01 30 sites
    Other conditions: Adenocarcinoma, Neoplasms
    View official trial listing →
  • Completed NCT NCT00112476

    Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

    Not yet reported National Cancer Institute (NCI) 24 participants 1 site
    Other conditions: Recurrent Melanoma, Recurrent Renal Cell Cancer, Stage IV Melanoma, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00112840

    CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer

    Not yet reported, Not yet reported National Cancer Institute (NCI) 60 participants Est. completion 2015-09-10 2 sites
    Other conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
    View official trial listing →
  • Completed NCT NCT00113360

    RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

    Not yet reported M.D. Anderson Cancer Center 67 participants Est. completion 2009-07 1 site
    Other conditions: Neuroendocrine Carcinoma, Islet Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT00117598

    Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

    Not yet reported Pfizer 169 participants Est. completion 2011-01 73 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT00121784

    Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients

    Not yet reported Hoffmann-La Roche 12 participants Est. completion 2006-08 29 sites
    Other conditions: Heart Transplantation
    View official trial listing →
  • Completed NCT NCT00121810

    Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients

    Not yet reported Hoffmann-La Roche 305 participants Est. completion 2009-11 36 sites Stand-alone
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00139386

    Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial

    Not yet reported Kumamoto University 1119 participants Est. completion 2012-04 1 site
    Cardiovascular disease Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00144677

    Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation

    Not yet reported Dana-Farber Cancer Institute 30 participants Est. completion 2006-06 1 site
    Other conditions: Acute Myelogenous Leukemia, Graft Versus Host Disease, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Non-Hodgkin's Lymphoma, Hodgkin's Disease
    View official trial listing →
  • Completed NCT NCT00146614

    Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation

    Not yet reported Dana-Farber Cancer Institute 105 participants Est. completion 2003-04 3 sites
    Other conditions: Graft Versus Host Disease, Hematologic Malignancies
    View official trial listing →
  • Completed NCT NCT00154284

    Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients

    Not yet reported Novartis 114 participants Est. completion 2008-07
    Other conditions: Organ Transplantation, Renal Transplantation
    View official trial listing →
  • Completed NCT NCT00154310

    Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

    Not yet reported Novartis 300 participants Est. completion 2008-09 3 sites
    Other conditions: Renal Transplantation
    View official trial listing →
  • Status unknown NCT NCT00166842

    Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets

    Not yet reported National Taiwan University Hospital 40 participants 1 site
    Other conditions: Transplantation, Kidney Transplantation, Immunosuppression
    View official trial listing →
  • Completed NCT NCT00167947

    Study Evaluating Sirolimus in Kidney Transplant Recipients.

    Not yet reported Wyeth is now a wholly owned subsidiary of Pfizer 150 participants Est. completion 2007-07 14 sites Stand-alone
    Other conditions: Kidney Failure, Graft vs Host Disease
    View official trial listing →
  • Completed NCT NCT00170794

    Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.

    Not yet reported Novartis Pharmaceuticals
    Other conditions: Cardiac Transplantation
    View official trial listing →
  • Completed NCT NCT00170859

    Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients

    Not yet reported Novartis Pharmaceuticals Est. completion 2006-12 1 site
    Other conditions: Heart Transplantation
    View official trial listing →
  • Completed NCT NCT00170885

    Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients

    Not yet reported Novartis Est. completion 2007-07 1 site
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00183248

    Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients

    Not yet reported, Not yet reported University of Miami 9 participants Est. completion 2009-11 1 site Stand-alone
    Other conditions: Kidney Transplantation, Kidney Disease, Kidney Failure
    View official trial listing →
  • Completed NCT NCT00188955

    Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney Transplant

    Not yet reported University of Manitoba 40 participants Est. completion 2008-10 1 site
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00189202

    Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans

    Not yet reported, Not yet reported University of Michigan 49 participants Est. completion 2008-07-01 1 site Stand-alone
    Other conditions: End Stage Renal Disease, Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00195195

    Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries

    Wyeth is now a wholly owned subsidiary of Pfizer 66 participants Est. completion 2008-06 3 sites
    Other conditions: Transplantation
    View official trial listing →
  • Completed NCT NCT00195429

    A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients

    Not yet reported Wyeth is now a wholly owned subsidiary of Pfizer 47 participants Est. completion 2007-10 1 site Stand-alone
    Other conditions: Kidney Failure, Graft vs Host Disease
    View official trial listing →
  • Status unknown NCT NCT00220558

    GISSOC II: Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary Occlusions

    Not yet reported Società Italiana di Cardiologia Invasiva 150 participants Est. completion 2010-02 14 sites
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT00223054

    Polymorphism of the Cytochrome P450-system in Renal Transplants

    University Hospital Schleswig-Holstein 200 participants Est. completion 2006-10 1 site
    Other conditions: Function of Renal Transplant
    View official trial listing →
  • Status unknown NCT NCT00229515

    Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI

    Not yet reported Marco Valgimigli 744 participants Est. completion 2012-03 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT00232739

    Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions

    Not yet reported Cordis US Corp. 100 participants Est. completion 2009-08 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT00232869

    A Study of the SMART Stent in the Treatment SFA Disease.

    Not yet reported Cordis US Corp. 93 participants Est. completion 2009-05 1 site Stand-alone
    Other conditions: Peripheral Artery Disease
    View official trial listing →
  • Completed NCT NCT00235170

    The Arterial Revascularization Therapies Study Part II.

    Not yet reported Cordis US Corp. 607 participants Est. completion 2009-04 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Terminated NCT NCT00240214

    Study Evaluating Rapamune in Patients After Kidney Transplantation

    Wyeth is now a wholly owned subsidiary of Pfizer 500 participants Est. completion 2008-02 1 site
    Other conditions: Renal Transplantation
    View official trial listing →
  • Completed NCT NCT00255658

    Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors

    Not yet reported National Cancer Institute (NCI) 40 participants Est. completion 2007-04 1 site
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00255788

    Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer

    Not yet reported NCIC Clinical Trials Group 49 participants Est. completion 2011-01-18 5 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00257387

    Study Evaluating Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese Kidney Transplants

    Not yet reported, Not yet reported Wyeth is now a wholly owned subsidiary of Pfizer 120 participants Est. completion 2006-08
    Other conditions: Kidney Transplant
    View official trial listing →
  • Completed NCT NCT00286624

    Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation

    Not yet reported, Not yet reported University of Minnesota 6 participants Est. completion 2006-08 1 site
    Other conditions: Type 1 Diabetes Mellitus, Hypoglycemia
    View official trial listing →
  • Completed NCT NCT00304954

    Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration

    Not yet reported National Eye Institute (NEI) 13 participants Est. completion 2010-01 1 site
    Other conditions: Age-Related Macular Degeneration, Choroidal Neovascularization
    View official trial listing →
  • Completed NCT NCT00305396

    Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation

    Not yet reported Vanderbilt University 80 participants Est. completion 2005-03 1 site
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00306397

    Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients

    Not yet reported University Hospital, Basel, Switzerland 100 participants Est. completion 2008-12 1 site
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Terminated NCT NCT00311311

    Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

    Not yet reported Pfizer 72 participants Est. completion 2012-01 8 sites Stand-alone
    Other conditions: Atherosclerosis, Kidney Failure
    View official trial listing →
  • Completed NCT NCT00317798

    Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

    Not yet reported University of Rochester 18 participants Est. completion 2011-04 1 site
    Other conditions: Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Status unknown NCT NCT00319878

    Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia

    Not yet reported, Not yet reported Office of Rare Diseases (ORD) 52 participants Est. completion 2009-12 4 sites Stand-alone
    Other conditions: Anemia, Aplastic
    View official trial listing →
  • Completed NCT NCT00331409

    Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

    Not yet reported OHSU Knight Cancer Institute 23 participants Est. completion 2010-01 1 site
    Other conditions: Kidney Cancer
    View official trial listing →
  • Completed NCT NCT00332397

    The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent Restenosis

    Not yet reported Deutsches Herzzentrum Muenchen 1007 participants Est. completion 2007-07 2 sites
    Other conditions: Coronary Disease
    View official trial listing →
  • Terminated NCT NCT00332839

    Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.

    Not yet reported Novartis Pharmaceuticals 93 participants Est. completion 2013-03 11 sites
    Other conditions: Renal Transplantation
    View official trial listing →
  • Completed NCT NCT00346918

    Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Not yet reported University of Zurich 100 participants Est. completion 2010-06 1 site
    Other conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    View official trial listing →
  • Completed NCT NCT00352443

    S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

    Not yet reported SWOG Cancer Research Network 66 participants Est. completion 2013-09 6 sites
    Other conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00352547

    Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation

    National Institutes of Health Clinical Center (CC) 93 participants Est. completion 2013-12-02 1 site
    Other conditions: Renal Transplant
    View official trial listing →
  • Completed NCT NCT00352976

    TBI Dose De-escalation for Fanconi Anemia

    Not yet reported, Not yet reported Masonic Cancer Center, University of Minnesota 83 participants Est. completion 2020-10-09 1 site Stand-alone
    Other conditions: Fanconi Anemia
    View official trial listing →
  • Completed NCT NCT00353301

    Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma

    Not yet reported University of Colorado, Denver 25 participants Est. completion 2012-03 1 site Stand-alone
    Other conditions: Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT00374140

    Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

    Not yet reported Ahmad Tarhini 40 participants Est. completion 2012-06 19 sites
    Other conditions: Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00375245

    Rapamycin With Grapefruit Juice for Advanced Malignancies

    Not yet reported University of Chicago 41 participants Est. completion 2012-05 1 site Stand-alone
    Other conditions: Tumors, Neoplasm Metastasis
    View official trial listing →
  • Completed NCT NCT00376688

    Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer

    Not yet reported National Cancer Institute (NCI) 31 participants Est. completion 2019-12-16 2 sites
    Other conditions: Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT00378612

    ACROSS-Cypher Total Occlusion Study of Coronary Arteries 4 Trial

    Not yet reported Sunil Rao 200 participants Est. completion 2012-09 16 sites Stand-alone
    Other conditions: Coronary Occlusions
    View official trial listing →
  • Completed NCT NCT00381420

    The Study of the BX Velocity Stent in the Treatment of De Novo Artery Lesions.

    Not yet reported Cordis US Corp. 100 participants Est. completion 2008-06 Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT00387400

    Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme

    Not yet reported NCIC Clinical Trials Group 32 participants Est. completion 2012-01-06 9 sites
    Other conditions: Brain and Central Nervous System Tumors
    View official trial listing →
  • Completed NCT NCT00397982

    Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma

    Not yet reported National Cancer Institute (NCI) 17 participants Est. completion 2013-07 2 sites
    Other conditions: Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
    View official trial listing →
  • Completed NCT NCT00398515

    Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 25 participants 1 site
    Other conditions: Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00402415

    Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy

    Not yet reported Yale University 18 participants Est. completion 2008-07 1 site
    Other conditions: Tumors
    View official trial listing →
  • Completed NCT NCT00402532

    Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation

    Not yet reported Hannover Medical School 190 participants Est. completion 2011-12 1 site
    Other conditions: Lung Transplantation
    View official trial listing →
  • Completed NCT NCT00411788

    A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer

    Not yet reported Yale University 11 participants Est. completion 2010-05 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00417677

    A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma

    Not yet reported, Not yet reported Wyeth is now a wholly owned subsidiary of Pfizer 124 participants Est. completion 2007-05 4 sites
    Other conditions: Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT00418067

    Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions

    Not yet reported Seung-Jung Park 2645 participants Est. completion 2009-01 20 sites
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT00422968

    Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease

    Not yet reported Seung-Jung Park 1454 participants Est. completion 2013-12 13 sites
    Cardiovascular disease
    View official trial listing →
  • Terminated NCT NCT00429052

    Mechanism of Percutaneous Revascularization for Coronary Bifurcation Disease

    University of Florida 24 participants Est. completion 2008-09 1 site
    Other conditions: Coronary Disease
    View official trial listing →
  • Completed NCT NCT00434174

    Safety of Everolimus and Pemetrexed in Lung Cancer Patients

    Not yet reported Novartis Pharmaceuticals 48 participants Est. completion 2010-12 5 sites
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00438919

    A Multi-center Post-Market Surveillance Registry

    Not yet reported Cordis US Corp. 15000 participants Est. completion 2009-12 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT00443937

    Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients

    Not yet reported Charite University, Berlin, Germany 15 participants Est. completion 2006-03 1 site
    Other conditions: Renal Transplantation
    View official trial listing →
  • Completed NCT NCT00449280

    Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies

    Not yet reported University of Chicago 34 participants Est. completion 2009-09 1 site
    Other conditions: Advanced Solid Tumor
    View official trial listing →
  • Completed NCT NCT00450320

    Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma

    Not yet reported AIDS Malignancy Consortium 7 participants Est. completion 2009-09 3 sites
    Other conditions: Sarcoma
    View official trial listing →
  • Terminated NCT NCT00452361

    Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient

    Not yet reported Wyeth is now a wholly owned subsidiary of Pfizer 31 participants Est. completion 2008-08 1 site Stand-alone
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00459186

    The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 19 participants Est. completion 2012-12 5 sites
    Other conditions: Metastatic, Androgen Independent Prostate Cancer, Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00464555

    Strategies to Improve Islet Survival

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 5 participants Est. completion 2014-02 2 sites Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT00468442

    B-Lymphocyte Immunotherapy in Islet Transplantation

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 2 participants Est. completion 2011-09 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00485030

    Diffuse Type In-Stent Restenosis After Drug-Eluting Stent

    Not yet reported Seung-Jung Park 60 participants Est. completion 2011-10 15 sites Stand-alone
    Other conditions: In-stent Restenosis
    View official trial listing →
  • Terminated NCT NCT00489164

    Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions

    Not yet reported, Not yet reported Cordis US Corp. 83 participants Est. completion 2004-05 11 sites
    Other conditions: Peripheral Vascular Diseases
    View official trial listing →
  • Completed NCT NCT00491517

    Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety

    Not yet reported Mario Negri Institute for Pharmacological Research 22 participants Est. completion 2009-08 1 site Stand-alone
    Other conditions: Polycystic Kidney
    View official trial listing →
  • Completed NCT NCT00498966

    Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

    Not yet reported AEterna Zentaris 50 participants Est. completion 2011-10 3 sites
    Other conditions: Kidney Cancer
    View official trial listing →
  • Completed NCT NCT00499486

    Sirolimus in Treating Patients With Advanced Pancreatic Cancer

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 47 participants Est. completion 2009-06 1 site Stand-alone
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Status unknown NCT NCT00499603

    Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

    Not yet reported M.D. Anderson Cancer Center 62 participants Est. completion 2017-04 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00502242

    Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus

    Not yet reported Pfizer 229 participants Est. completion 2013-09 49 sites
    Other conditions: Kidney Transplant
    View official trial listing →
  • Completed NCT NCT00510068

    Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors

    Not yet reported Novartis Pharmaceuticals 410 participants Est. completion 2014-03 82 sites
    Other conditions: Advanced Neuroendocrine Tumors of Pancreatic Origin
    View official trial listing →
  • Completed NCT NCT00518271

    Study Comparing Standard Dose and Reduced Dose Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients

    Not yet reported Wyeth is now a wholly owned subsidiary of Pfizer 120 participants Est. completion 2002-06
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00519116

    Study Comparing Standard Dose and Reduced Dose Tacrolimus With Sirolimus in Renal Transplant Patients

    Not yet reported Wyeth is now a wholly owned subsidiary of Pfizer 150 participants Est. completion 2001-08
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00525889

    Proleukin and Rapamune in Type 1 Diabetes

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 9 participants Est. completion 2013-09 3 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Terminated NCT NCT00526591

    Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer

    Not yet reported Jorge A. Garcia, MD 17 participants Est. completion 2011-08 1 site
    Other conditions: Prostate Cancer
    View official trial listing →
  • Status unknown NCT NCT00544999

    Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia

    Not yet reported Institut de Recherche Clinique sur les Cancers et le Sang 21 participants 1 site
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00563147

    A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma

    Not yet reported AVEO Pharmaceuticals, Inc. 28 participants Est. completion 2011-02 5 sites
    Other conditions: Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT00566813

    Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

    Not yet reported, Not yet reported University of Illinois at Chicago 10 participants Est. completion 2020-07-15 1 site
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT00570921

    Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

    Not yet reported Mara Chambers 33 participants Est. completion 2015-01 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00576680

    RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 43 participants Est. completion 2019-03-29 3 sites
    Other conditions: Pancreatic Neuroendocrine Tumor
    View official trial listing →
  • Terminated NCT NCT00582738

    Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection

    Not yet reported Novartis Pharmaceuticals 43 participants Est. completion 2010-01 1 site
    Other conditions: Recurrent Hepatitis C
    View official trial listing →
  • Completed NCT NCT00583063

    Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers

    Not yet reported University of Chicago 23 participants Est. completion 2008-04 1 site
    Other conditions: Solid Tumors
    View official trial listing →
  • Completed NCT NCT00586443

    BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)

    Not yet reported Herbert Hurwitz, MD 56 participants Est. completion 2014-09 1 site
    Other conditions: Solid Tumors
    View official trial listing →
  • Completed NCT NCT00610012

    Tumor Registry of Advanced Renal Cell Carcinoma

    iOMEDICO AG 1500 participants Est. completion 2020-05-15 1 site
    Other conditions: Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT00611910

    Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions

    Not yet reported Deutsches Herzzentrum Muenchen 610 participants Est. completion 2011-03 4 sites Stand-alone
    Other conditions: Arteriosclerosis of Arterial Coronary Artery Bypass Graft
    View official trial listing →
  • Terminated NCT NCT00651482

    Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

    Not yet reported Sandy Srinivas 10 participants Est. completion 2012-03 1 site
    Other conditions: Kidney Neoplasms, Kidney (Renal Cell) Cancer
    View official trial listing →
  • No Longer Available NCT NCT00655252

    Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

    Novartis Pharmaceuticals 84 sites
    Other conditions: Metastatic Renal Cell Cancer
    View official trial listing →
  • Completed NCT NCT00655655

    Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

    Not yet reported Mayo Clinic 96 participants Est. completion 2018-01-11 1 site
    Other conditions: Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00667485

    Rapamycin Plus Bevacizumab in Advanced Cancers

    Not yet reported University of Chicago 28 participants Est. completion 2012-05 1 site
    Other conditions: Advanced Cancer, Metastatic Cancer
    View official trial listing →
  • Completed NCT NCT00670423

    A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation

    Not yet reported Jennifer E. Schwartz 27 participants Est. completion 2013-10-16 1 site
    Other conditions: Graft vs Host Disease, Peripheral Blood Stem Cell Transplantation, Transplantation, Homologous
    View official trial listing →
  • Completed NCT NCT00688753

    RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe

    Not yet reported Novartis Pharmaceuticals 92 participants Est. completion 2014-10 19 sites
    Other conditions: Carcinoma, Renal Cell, Non Clear Cell Renal Carcinoma, Papillary Cell Renal Carcinoma, Adenocarcinoma
    View official trial listing →
  • Completed NCT NCT00691015

    Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

    Not yet reported Barbara Ann Karmanos Cancer Institute 48 participants Est. completion 2014-04 1 site
    Other conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
    View official trial listing →
  • Status unknown NCT NCT00693030

    Optical Coherence Tomography for Drug Eluting Stent Safety

    Not yet reported A.O. Ospedale Papa Giovanni XXIII 77 participants Est. completion 2008-12 1 site
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT00693251

    Optimal Stenting Strategy For True Bifurcation Lesions

    Not yet reported Seung-Jung Park 420 participants Est. completion 2015-06 12 sites
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT00693433

    Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 15 participants 1 site
    Other conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT00693446

    A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids

    Not yet reported Nantes University Hospital 118 participants Est. completion 2017-04 1 site
    Other conditions: Pancreas Transplantation, Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00697112

    Study Evaluating The Use Of Sirolimus In Recipients Of Kidney Allografts From Expanded Criteria Donors (ECD)

    Pfizer 53 participants Est. completion 2012-12 8 sites
    Other conditions: Renal Transplantation
    View official trial listing →
  • Completed NCT NCT00698607

    Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing

    Not yet reported Seoul National University Hospital 1466 participants Est. completion 2014-04 1 site
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT00703625

    Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies

    Not yet reported Washington University School of Medicine 26 participants Est. completion 2011-06-01 1 site
    Other conditions: Resistant Solid Malignancies
    View official trial listing →
  • Active, not recruiting NCT NCT00706420

    Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen

    Not yet reported City of Hope Medical Center 17 participants Est. completion 2026-10-12 1 site Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00708591

    Study of Rapamycin Plus Ketoconazole in Advanced Cancers

    Not yet reported University of Chicago 57 participants Est. completion 2008-12 1 site
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT00714623

    The SCRIPPS DES REAL WORLD Registry

    Paul S Teirstein, MD 859 participants Est. completion 2012-04 1 site
    Cardiovascular disease Other conditions: Coronary Restenosis, Coronary Thrombosis
    View official trial listing →
  • Status unknown NCT NCT00715884

    Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems

    Not yet reported Cordis US Corp. 678 participants Est. completion 2014-09 1 site Stand-alone
    Cardiovascular disease Other conditions: Coronary Atherosclerosis
    View official trial listing →
  • Completed NCT NCT00723255

    Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

    Not yet reported National Cancer Institute (NCI) 53 participants Est. completion 2016-01-25 41 sites
    Other conditions: Recurrent Endometrial Carcinoma
    View official trial listing →
  • Terminated NCT NCT00727207

    Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy

    Not yet reported Technical University of Munich 35 participants Est. completion 2014-09 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00743509

    A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma

    Not yet reported University of Michigan Rogel Cancer Center 49 participants Est. completion 2012-09 1 site Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Completed NCT NCT00756340

    A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors

    Not yet reported St. Jude Children's Research Hospital 16 participants Est. completion 2015-09 1 site
    Other conditions: Recurrent or Refractory Solid Tumors, CNS Malignancies
    View official trial listing →
  • Completed NCT NCT00759850

    Drug Eluting Stent (DES) in Primary Angioplasty

    Not yet reported, Not yet reported San Giuseppe Moscati Hospital 270 participants Est. completion 2007-12 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT00775073

    Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001

    Not yet reported Gerhard Treiber 33 participants Est. completion 2012-04 10 sites
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Terminated NCT NCT00776373

    Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies

    Not yet reported, Not yet reported Abramson Cancer Center at Penn Medicine 4 participants Est. completion 2009-12 1 site
    Other conditions: ALL, Burkitt's Lymphoma, Lymphoblastic Leukemia, CML
    View official trial listing →
  • Withdrawn NCT NCT00777400

    Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells

    Not yet reported, Not yet reported University of California, San Francisco Est. completion 2009-04 1 site Stand-alone
    Other conditions: Autoimmune Diseases
    View official trial listing →
  • Completed NCT NCT00782626

    Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

    Not yet reported Dana-Farber Cancer Institute 23 participants Est. completion 2012-08 10 sites
    Other conditions: Glioma, Low-grade Glioma, Astrocytoma
    View official trial listing →
  • Completed NCT NCT00788060

    A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma

    Not yet reported Daniel George, MD 5 participants Est. completion 2012-12 1 site
    Other conditions: Renal Cell Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT00788580

    S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors

    Not yet reported SWOG Cancer Research Network
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00800722

    A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.

    Not yet reported University of California, Irvine 21 participants Est. completion 2014-06 1 site
    Other conditions: Port Wine Stain
    View official trial listing →
  • Completed NCT NCT00800917

    A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme

    Not yet reported Rigshospitalet, Denmark 12 participants Est. completion 2010-02 1 site
    Other conditions: Glioblastoma Multiforme
    View official trial listing →
  • Terminated NCT NCT00807755

    Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

    Not yet reported University of California, Davis 5 participants Est. completion 2011-12 1 site
    Other conditions: Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00814944

    A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

    Not yet reported Santen Inc. 143 participants Est. completion 2009-10 1 site Stand-alone
    Other conditions: Dry Eye
    View official trial listing →
  • Completed NCT NCT00820911

    Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients

    Not yet reported Novartis Pharmaceuticals 175 participants Est. completion 2012-07 28 sites
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00830466

    A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.

    Not yet reported University of California, Irvine 22 participants Est. completion 2016-01 1 site
    Other conditions: Port Wine Stain
    View official trial listing →
  • Terminated NCT NCT00831480

    Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal

    Not yet reported Linda C. Higgins 15 participants Est. completion 2014-12 2 sites
    Other conditions: Kidney Cancer
    View official trial listing →
  • Terminated NCT NCT00857259

    The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration

    Not yet reported Novartis Pharmaceuticals 16 participants 12 sites
    Other conditions: Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
    View official trial listing →
  • Completed NCT NCT00861874

    A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported University of Rochester 13 participants 1 site
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00862979

    A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients

    Not yet reported Novartis Pharmaceuticals 162 participants Est. completion 2017-03-06 9 sites
    Other conditions: Heart Transplantation
    View official trial listing →
  • Completed NCT NCT00866879

    Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

    Not yet reported Northwestern University 275 participants Est. completion 2019-03 1 site Stand-alone
    Other conditions: Renal Transplant Rejection
    View official trial listing →
  • Completed NCT NCT00886691

    Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

    Not yet reported GOG Foundation 150 participants Est. completion 2015-03-23 45 sites
    Other conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
    View official trial listing →
  • Terminated NCT NCT00887640

    Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer

    Not yet reported Duke University 11 participants Est. completion 2012-08 2 sites
    Other conditions: Prostate Cancer
    View official trial listing →
  • Status unknown NCT NCT00890253

    Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation

    Not yet reported Armin Goralczyk 29 participants Est. completion 2013-01 1 site
    Other conditions: Liver Transplantation, Chronic Renal Insufficiency
    View official trial listing →
  • Completed NCT NCT00896012

    Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal

    Not yet reported University at Buffalo 58 participants Est. completion 2011-12 1 site Stand-alone
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00903175

    Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

    Not yet reported Novartis Pharmaceuticals 471 participants Est. completion 2015-05 84 sites
    Other conditions: Renal Cell Carcinoma
    View official trial listing →
  • Status unknown NCT NCT00903188

    Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation

    Not yet reported University Hospital, Antwerp 152 participants Est. completion 2015-04 5 sites
    Other conditions: Renal Transplantation
    View official trial listing →
  • Status unknown NCT NCT00905008

    Long-Term Safety of Drug Eluting Stents in the "Real World" (FReIburger STent Registry)

    University Hospital Freiburg 1502 participants
    Other conditions: Stent Thrombosis
    View official trial listing →
  • Completed NCT NCT00908466

    Sirolimus as Therapeutic Approach to Uveitis

    Not yet reported Johns Hopkins University 30 participants Est. completion 2013-02 1 site Stand-alone
    Other conditions: Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
    View official trial listing →
  • Completed NCT NCT00928798

    Topical Rapamycin for Fibrofolliculomas

    Not yet reported Maastricht University Medical Center 19 participants Est. completion 2011-08 2 sites
    Other conditions: Birt-Hogg-Dubé Syndrome
    View official trial listing →
  • Terminated NCT NCT00938119

    Care China-Diabetes

    Johnson & Johnson Medical, China 1603 participants Est. completion 2012-12 46 sites
    Cardiovascular disease Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT00942682

    Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

    Not yet reported Dana-Farber Cancer Institute 21 participants Est. completion 2013-03 1 site
    Other conditions: Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
    View official trial listing →
  • Completed NCT NCT00943956

    Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer

    Not yet reported Institut du Cancer de Montpellier - Val d'Aurelle 30 participants Est. completion 2012-12 1 site
    Other conditions: Prostate Cancer
    View official trial listing →
  • Terminated NCT NCT00956293

    Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program

    Not yet reported Novartis Pharmaceuticals 207 participants Est. completion 2013-03 9 sites
    Other conditions: Renal Transplantation
    View official trial listing →
  • Withdrawn NCT NCT00957320

    Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)

    Not yet reported Emory University Est. completion 2012-08 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT00962507

    Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

    Not yet reported City of Hope Medical Center 11 participants Est. completion 2013-01 2 sites
    Other conditions: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00967044

    Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 31 participants Est. completion 2014-03 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT00972335

    Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

    Not yet reported SCRI Development Innovations, LLC 18 participants Est. completion 2014-07 7 sites
    Other conditions: Intracranial Meningioma
    View official trial listing →
  • Active, not recruiting NCT NCT00977574

    Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

    Not yet reported National Cancer Institute (NCI) 349 participants Est. completion 2027-03-06 230 sites
    Obstructive sleep apnea Other conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm
    View official trial listing →
  • Active, not recruiting NCT NCT00977691

    Haploidentical PBMC Transplant for Severe Congenital Anemias

    Not yet reported, Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 23 participants Est. completion 2026-09-10 1 site Stand-alone
    Other conditions: Sickle Cell Anemia
    View official trial listing →
  • Completed NCT NCT00981162

    Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

    Not yet reported Roswell Park Cancer Institute 12 participants Est. completion 2012-12 2 sites
    Other conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Terminated NCT NCT00985374

    A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

    Not yet reported Hoffmann-La Roche 11 participants Est. completion 2013-06 3 sites
    Other conditions: Neoplasms
    View official trial listing →
  • Completed NCT NCT00998036

    Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

    Not yet reported Columbia University 9 participants Est. completion 2012-10 1 site
    Other conditions: Triple Negative Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01009801

    Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

    Not yet reported, Not yet reported Swiss Cancer Institute 27 participants Est. completion 2015-06 8 sites
    Other conditions: Liver Cancer
    View official trial listing →
  • Completed NCT NCT01014234

    Rapamycin and Regulatory T Cells in Kidney Transplantation

    Not yet reported Fondazione IRCCS Policlinico San Matteo di Pavia 56 participants Est. completion 2013-06 1 site
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT01019434

    Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 111 participants Est. completion 2014-03 13 sites
    Other conditions: Brain and Central Nervous System Tumors
    View official trial listing →
  • Completed NCT NCT01023815

    Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.

    Not yet reported Novartis 330 participants Est. completion 2012-07 28 sites
    Other conditions: de Novo Kidney Transplant Recipients, Renal Transplantation
    View official trial listing →
  • Completed NCT NCT01024946

    Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

    Not yet reported Memorial Sloan Kettering Cancer Center 11 participants Est. completion 2012-07 3 sites
    Other conditions: Malignant Pleural Mesothelioma
    View official trial listing →
  • Completed NCT NCT01026402

    Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

    Not yet reported AstraZeneca 172 participants Est. completion 2014-08 2 sites
    Other conditions: Advanced Solid Malignancies
    View official trial listing →
  • Completed NCT NCT01028092

    mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation

    Not yet reported University Hospital, Brest 327 participants Est. completion 2014-07 18 sites
    Other conditions: Renal Transplant
    View official trial listing →
  • Completed NCT NCT01031901

    Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)

    Not yet reported The University of Texas Health Science Center, Houston 52 participants Est. completion 2011-06 1 site Stand-alone
    Other conditions: Tuberous Sclerosis, Neurofibromatoses, Angiofibroma, Neurofibroma
    View official trial listing →
  • Status unknown NCT NCT01034371

    Comparison of One-stop Hybrid Revascularization Versus Off-pump Coronary Artery Bypass for the Treatment of Multi-vessel Disease

    Not yet reported China National Center for Cardiovascular Diseases 400 participants 2 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Status unknown NCT NCT01035034

    Comparison of One-stop Hybrid Revascularization Versus Percutaneous Coronary Intervention for the Treatment of Multi-vessel Disease

    Not yet reported China National Center for Cardiovascular Diseases 480 participants 2 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT01035229

    Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

    Not yet reported Novartis Pharmaceuticals 546 participants Est. completion 2013-10 131 sites
    Other conditions: Carcinoma
    View official trial listing →
  • Completed NCT NCT01042782

    Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction

    Not yet reported Krankenhaus Nordwest 16 participants Est. completion 2012-08 1 site
    Other conditions: Advanced Gastric Cancer, Advanced Cancer of the Esophagogastric Junction
    View official trial listing →
  • Completed NCT NCT01049841

    Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

    Not yet reported Memorial Sloan Kettering Cancer Center 23 participants Est. completion 2017-03 1 site
    Other conditions: Pediatric Solid Tumors
    View official trial listing →
  • Completed NCT NCT01051557

    Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 36 participants Est. completion 2020-09-30 1 site
    Obstructive sleep apnea Other conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Neoplasm
    View official trial listing →
  • Completed NCT NCT01070316

    Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)

    Not yet reported, Not yet reported Children's Hospital Medical Center, Cincinnati 20 participants Est. completion 2016-04 2 sites
    Other conditions: Epilepsy, Tuberous Sclerosis Complex
    View official trial listing →
  • Withdrawn NCT NCT01073111

    Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents

    Not yet reported Hyogo Medical University Est. completion 2017-02 1 site
    Cardiovascular disease Other conditions: Atherosclerosis
    View official trial listing →
  • Completed NCT NCT01074086

    Phase I Study in RAD 001 Patients With Relapse AML

    Not yet reported French Innovative Leukemia Organisation 31 participants Est. completion 2012-12 1 site
    Other conditions: AML
    View official trial listing →
  • Completed NCT NCT01076543

    Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 110 participants Est. completion 2018-09-30 11 sites
    Other conditions: AIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Status unknown NCT NCT01079702

    Everolimus and Capecitabine in Patients With Advanced Malignancy

    Not yet reported, Not yet reported Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 35 participants Est. completion 2011-01 2 sites
    Other conditions: Advanced Malignancies
    View official trial listing →
  • Status unknown NCT NCT01088893

    Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy

    Not yet reported Organisation for Oncology and Translational Research 50 participants Est. completion 2013-03 1 site
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Terminated NCT NCT01096199

    A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)

    Not yet reported National University Hospital, Singapore 35 participants 1 site
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT01099527

    A Trial of RAD001/Capecitabine in Refractory Gastric Cancer

    Not yet reported, Not yet reported Samsung Medical Center 59 participants Est. completion 2013-12 1 site
    Other conditions: Metastatic Gastric Cancer
    View official trial listing →
  • Completed NCT NCT01107509

    Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers

    Not yet reported St. Joseph's Healthcare Hamilton 20 participants Est. completion 2017-10-01 1 site
    Other conditions: Carcinoma, Renal Cell
    View official trial listing →
  • Completed NCT NCT01108445

    Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

    Not yet reported Duke University 131 participants Est. completion 2015-04 18 sites
    Other conditions: Advanced Non-clear Cell Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT01120028

    Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy

    Not yet reported, Not yet reported University of Oxford 852 participants Est. completion 2020-03 20 sites Stand-alone
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT01127763

    RAD001 Plus Carboplatin in Breast Cancer Patients

    Not yet reported NYU Langone Health 25 participants Est. completion 2013-03 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01136733

    A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

    Not yet reported, Not yet reported Eisai Inc. 173 participants Est. completion 2018-02-08 37 sites
    Other conditions: Metastatic Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT01141244

    Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors

    Not yet reported National Cancer Institute (NCI) 72 participants 25 sites
    Other conditions: Unspecified Childhood Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT01143779

    FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

    Not yet reported M.D. Anderson Cancer Center 3 participants Est. completion 2021-12-27 1 site
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT01152840

    Study of RAD001 in Adenoid Cystic Carcinoma

    Not yet reported Seoul National University Hospital 33 participants Est. completion 2012-12 1 site
    Other conditions: Adenoid Cystic Carcinoma
    View official trial listing →
  • Completed NCT NCT01169701

    24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients

    Not yet reported Novartis Pharmaceuticals 71 participants Est. completion 2014-03 9 sites
    Other conditions: Renal Transplant
    View official trial listing →
  • Completed NCT NCT01182168

    Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

    Not yet reported Memorial Sloan Kettering Cancer Center 12 participants Est. completion 2016-03 1 site
    Other conditions: Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
    View official trial listing →
  • Withdrawn NCT NCT01182883

    A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

    Not yet reported National Cancer Institute (NCI) Est. completion 2012-04-04
    Other conditions: Brain Stem Neoplasms, Glioma, Pinealoma
    View official trial listing →
  • Completed NCT NCT01183247

    An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens

    Not yet reported University Hospital, Basel, Switzerland 63 participants Est. completion 2010-06 1 site
    Other conditions: Comparative Study, Immunosuppressive Agents
    View official trial listing →
  • Completed NCT NCT01183663

    Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

    Not yet reported M.D. Anderson Cancer Center 180 participants Est. completion 2016-05 1 site
    Other conditions: Advanced Cancers
    View official trial listing →
  • Withdrawn NCT NCT01188889

    RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

    Not yet reported, Not yet reported University of Michigan Rogel Cancer Center Est. completion 2017-12 1 site
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Withdrawn NCT NCT01194193

    Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours

    Not yet reported AstraZeneca 63 participants
    Other conditions: Cancer, Advanced Solid Tumours, Lymphomas
    View official trial listing →
  • Terminated NCT NCT01204450

    Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma

    Not yet reported UNC Lineberger Comprehensive Cancer Center 7 participants Est. completion 2013-03 2 sites
    Other conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT01204476

    Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

    Not yet reported National Cancer Institute (NCI) 27 participants 1 site
    Other conditions: Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
    View official trial listing →
  • Completed NCT NCT01206764

    A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

    Not yet reported Novartis Pharmaceuticals 143 participants Est. completion 2017-07-01 22 sites
    Other conditions: Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT01218555

    Study of Everolimus (RAD001) in Combination With Lenalidomide

    Not yet reported Emory University 44 participants Est. completion 2020-11-05 2 sites
    Other conditions: Solid Organ Malignancies, Adenoidcystic Carcinoma, Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT01220856

    Reparixin in Pancreatic Islet Transplantation

    Not yet reported Dompé Farmaceutici S.p.A 9 participants Est. completion 2013-04-30 2 sites
    Other conditions: Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01223027

    Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

    Not yet reported Novartis Pharmaceuticals 564 participants Est. completion 2014-06 199 sites
    Other conditions: Metastatic Renal Cell Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT01234974

    IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus

    Not yet reported Milton S. Hershey Medical Center Est. completion 2013-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01239342

    Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

    Not yet reported National Cancer Institute (NCI) 43 participants Est. completion 2018-09-19 8 sites
    Other conditions: Metastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
    View official trial listing →
  • Completed NCT NCT01239472

    Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant

    Not yet reported Andre Barreto Pereira 30 participants Est. completion 2015-06 1 site
    Other conditions: Renal Transplant Rejection, Immunosuppression
    View official trial listing →
  • Status unknown NCT NCT01246817

    Temsirolimus-RCC-imaging

    Not yet reported Radboud University Medical Center 51 participants 1 site
    Other conditions: Renal Cell Cancer
    View official trial listing →
  • Completed NCT NCT01248403

    A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy

    Not yet reported Krankenhaus Nordwest 300 participants Est. completion 2019-10 1 site
    Other conditions: Advanced Gastric Cancer, Esophagogastric Junction Cancer
    View official trial listing →
  • Completed NCT NCT01251575

    Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

    Not yet reported Fred Hutchinson Cancer Center 77 participants Est. completion 2019-02-11 5 sites Stand-alone
    Other conditions: Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, Adult Myelodysplastic Syndrome, Adult Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Diffuse Large B-Cell Lymphoma, Childhood Myelodysplastic Syndrome, Childhood Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Mantle Cell Lymphoma, Plasma Cell Myeloma, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia, Waldenstrom Macroglobulinemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT01256385

    Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

    Not yet reported National Cancer Institute (NCI) 86 participants Est. completion 2013-12 24 sites
    Other conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Squamous Cell Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Verrucous Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Verrucous Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Oral Cavity Verrucous Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Verrucous Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Major Salivary Gland Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Oral Cavity Verrucous Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
    View official trial listing →
  • Completed NCT NCT01259063

    RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 33 participants Est. completion 2017-06 1 site
    Other conditions: Bladder Cancer
    View official trial listing →
  • Status unknown NCT NCT01263951

    Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

    Not yet reported Thomas Jefferson University 35 participants Est. completion 2022-05 1 site
    Other conditions: Differentiated Thyroid Cancer
    View official trial listing →
  • Completed NCT NCT01289912

    Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)

    Not yet reported Mustafa Sahin 52 participants Est. completion 2014-12 2 sites
    Other conditions: Tuberous Sclerosis Complex
    View official trial listing →
  • Completed NCT NCT01305941

    A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

    Not yet reported UNC Lineberger Comprehensive Cancer Center 32 participants Est. completion 2017-10-16 4 sites
    Other conditions: HER-2 Positive Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01313390

    Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer

    Not yet reported, Not yet reported University College, London 4 participants Est. completion 2011-04 1 site
    Other conditions: Head and Neck Cancer
    View official trial listing →
  • Terminated NCT NCT01313923

    Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus

    Not yet reported University of California, Irvine 3 participants Est. completion 2014-10 1 site Stand-alone
    Other conditions: Pemphigus
    View official trial listing →
  • Terminated NCT NCT01318915

    Research Study of ATG and Rituximab in Renal Transplantation

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 10 participants Est. completion 2017-08-25 6 sites Stand-alone
    Other conditions: Renal Transplant Recipients
    View official trial listing →
  • Withdrawn NCT NCT01326468

    Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Est. completion 2016-12
    Other conditions: Head and Neck Cancer
    View official trial listing →
  • Completed NCT NCT01334073

    Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors

    Not yet reported University Hospital, Bordeaux 19 participants Est. completion 2015-01 2 sites
    Other conditions: Malignant Advanced Solid Tumors, Carcinoma, Renal Cell
    View official trial listing →
  • Completed NCT NCT01338090

    89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors

    University Medical Center Groningen 14 participants Est. completion 2012-03 1 site
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Terminated NCT NCT01345136

    Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

    Not yet reported Jonsson Comprehensive Cancer Center 4 participants Est. completion 2024-02-06 1 site
    Other conditions: Neurofibromatosis Type 2, Neuroma, Acoustic
    View official trial listing →
  • Terminated NCT NCT01365468

    Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

    Not yet reported Novartis Pharmaceuticals 9 participants Est. completion 2015-04 2 sites
    Other conditions: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
    View official trial listing →
  • Completed NCT NCT01403415

    Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

    Not yet reported National Cancer Institute (NCI) 13 participants 31 sites
    Other conditions: Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma
    View official trial listing →
  • Completed NCT NCT01404104

    Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma

    Not yet reported St. Joseph's Healthcare Hamilton 11 participants Est. completion 2014-08 1 site
    Other conditions: Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT01412892

    Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas

    Not yet reported Assistance Publique - Hôpitaux de Paris 30 participants Est. completion 2014-10 1 site
    Other conditions: Neurofibromatosis Type 1, Plexiform Neurofibroma, Neurofibromatoses
    View official trial listing →
  • Terminated NCT NCT01420081

    A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

    Not yet reported Pfizer 67 participants Est. completion 2015-12-25 51 sites
    Other conditions: Endometrial Neoplasms
    View official trial listing →
  • Status unknown NCT NCT01423708

    Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study

    Not yet reported Azienda Ospedaliera di Padova 117 participants Est. completion 2014-01 7 sites
    Other conditions: Liver Failure, Liver Diseases, Liver Cirrhosis, Liver Neoplasms
    View official trial listing →
  • Status unknown NCT NCT01428973

    Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens

    Not yet reported University of Liege 200 participants Est. completion 2024-12 13 sites Stand-alone
    Other conditions: Graft-Versus-Host Disease, Hematological Malignancies
    View official trial listing →
  • Completed NCT NCT01451879

    Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies

    University of Florida 11 participants Est. completion 2017-10 1 site
    Other conditions: Pompe Disease
    View official trial listing →
  • Completed NCT NCT01453504

    Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma

    Not yet reported, Not yet reported University of Cologne 73 participants Est. completion 2019-03 1 site
    Other conditions: Hodgkin Lymphoma
    View official trial listing →
  • Status unknown NCT NCT01455649

    Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults

    Not yet reported Deise de Boni Monteiro de Carvalho 30 participants Est. completion 2013-11 1 site
    Other conditions: Kidney Transplant, Immunosuppression
    View official trial listing →
  • Completed NCT NCT01460979

    Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma

    Not yet reported AGO Study Group 47 participants Est. completion 2015-11 18 sites
    Other conditions: Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Endometrial Neoplasms
    View official trial listing →
  • Completed NCT NCT01466231

    Everolimus in Refractory Testicular Germ Cell Cancer

    Not yet reported National Cancer Institute, Slovakia 15 participants Est. completion 2015-06 1 site
    Other conditions: Germ Cell Tumor
    View official trial listing →
  • Completed NCT NCT01473095

    Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

    Not yet reported ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 120 participants Est. completion 2017-08-07 7 sites
    Other conditions: Solid Tumor, Malignant Lymphoma, Tumor
    View official trial listing →
  • Terminated NCT NCT01473732

    Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity

    Not yet reported Montefiore Medical Center 2 participants Est. completion 2012-08 1 site
    Other conditions: Chronic Allograft Injury, Calcineurin Inhibitor Toxicity
    View official trial listing →
  • Terminated NCT NCT01499160

    Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

    Not yet reported University of Maryland, Baltimore 7 participants Est. completion 2016-12 1 site
    Other conditions: Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis
    View official trial listing →
  • Completed NCT NCT01509560

    PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood

    Not yet reported Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 21 participants Est. completion 2016-04-30 1 site
    Other conditions: Condition After Allogenic Peripheral Stem Cell Transplantation (SCT)
    View official trial listing →
  • Completed NCT NCT01510119

    Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma

    Not yet reported, Not yet reported Abramson Cancer Center at Penn Medicine 40 participants Est. completion 2017-01-05 3 sites
    Other conditions: Metastatic Clear Cell Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT01516723

    Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions

    Not yet reported R&D Cardiologie 330 participants Est. completion 2020-12-31 4 sites Stand-alone
    Cardiovascular disease Other conditions: Coronary Disease, Coronary Stenosis
    View official trial listing →
  • Completed NCT NCT01517243

    Phase II Study of Alternating Sunitinib and Temsirolimus

    Not yet reported Dartmouth-Hitchcock Medical Center 37 participants Est. completion 2018-08-20 2 sites
    Other conditions: Metastatic Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT01545947

    Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

    Not yet reported Celgene 76 participants Est. completion 2014-12-11 9 sites
    Other conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
    View official trial listing →
  • Status unknown NCT NCT01567930

    Temsirolimus as Second-line Therapy in HCC

    Not yet reported University of Tennessee Cancer Institute 25 participants Est. completion 2013-03 1 site
    Other conditions: Unresectable or Metastatic Hepatocellular Carcinoma
    View official trial listing →
  • Terminated NCT NCT01582009

    Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

    Not yet reported, Not yet reported Roswell Park Cancer Institute 26 participants Est. completion 2015-12 2 sites
    Other conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
    View official trial listing →
  • Completed NCT NCT01601821

    Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids

    Not yet reported Pfizer 245 participants Est. completion 2008-03 4 sites
    Other conditions: Inflammation
    View official trial listing →
  • Status unknown NCT NCT01608412

    A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus

    Not yet reported Hospital de Clinicas de Porto Alegre 120 participants Est. completion 2014-07 1 site
    Other conditions: Kidney Transplant Recipients
    View official trial listing →
  • Terminated NCT NCT01609673

    Study of Everolimus in de Novo Renal Transplant Recipients

    Not yet reported Helady Pinheiro, MD, PhD 1 participants Est. completion 2013-05 4 sites
    Other conditions: End Stage Renal Failure With Renal Transplant
    View official trial listing →
  • Completed NCT NCT01614197

    A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

    Not yet reported Therapeutic Advances in Childhood Leukemia Consortium 16 participants Est. completion 2020-09-04 32 sites
    Other conditions: Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT01614301

    Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma

    Not yet reported, Not yet reported University of Regensburg 136 participants Est. completion 2016-05 1 site
    Other conditions: Advanced Melanoma
    View official trial listing →
  • Completed NCT NCT01620307

    Rapamune Improves Outcomes of Severe H1N1 Pneumonia

    Not yet reported Chang Gung Memorial Hospital 38 participants Est. completion 2011-12
    Other conditions: H1N1 Pneumonia, Hypoxemia
    View official trial listing →
  • Completed NCT NCT01625156

    Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery

    Not yet reported National Cancer Institute (NCI) 11 participants Est. completion 2015-10 2 sites
    Other conditions: Adult Solid Neoplasm
    View official trial listing →
  • Terminated NCT NCT01627067

    Exemestane-RAD001-Metformin

    Not yet reported M.D. Anderson Cancer Center 23 participants Est. completion 2019-02-01 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01628913

    Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

    Not yet reported Novartis Pharmaceuticals 62 participants Est. completion 2014-09 26 sites
    Other conditions: Pancreatic Neuroendocrine Tumors (pNET)
    View official trial listing →
  • Completed NCT NCT01634217

    Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation

    Not yet reported Masonic Cancer Center, University of Minnesota 16 participants Est. completion 2018-12-01 1 site Stand-alone
    Other conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
    View official trial listing →
  • Terminated NCT NCT01636466

    The Everolimus-Transplant Exit Strategy Trial (E-TEST)

    Not yet reported Ashtar Chami 1 participants Est. completion 2014-05 1 site
    Other conditions: Kidney Failure, Chronic
    View official trial listing →
  • Completed NCT NCT01637194

    Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer

    Not yet reported Fox Chase Cancer Center 12 participants Est. completion 2011-07 1 site
    Other conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Colon Cancer, Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Colon Cancer, Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Tongue Cancer
    View official trial listing →
  • Terminated NCT NCT01675947

    Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy

    Not yet reported National Eye Institute (NEI) 52 participants Est. completion 2016-02 13 sites Stand-alone
    Other conditions: Geographic Atrophy
    View official trial listing →
  • Completed NCT NCT01706471

    Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation

    Not yet reported Yonsei University 60 participants Est. completion 2013-04 1 site
    Other conditions: Planned Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT01756118

    A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia

    Not yet reported Goethe University 24 participants Est. completion 2020-02-07 1 site
    Other conditions: Acute Lymphoblastic Leukemia, Leukemia, Myelocytic, Acute, Chronic Myelogenous Leukemia With Crisis of Blast Cells
    View official trial listing →
  • Completed NCT NCT01756807

    EGO-COMBO Angiographic Extension Study

    Not yet reported Prof. Stephen Lee 41 participants Est. completion 2013-06 1 site Stand-alone
    Other conditions: Coronary Disease
    View official trial listing →
  • Status unknown NCT NCT01777204

    Gastrointestinal Transit and Motility in Renal Transplant Recipients

    Universidade Estadual de Ciências da Saúde de Alagoas 20 participants Est. completion 2013-01 1 site
    Other conditions: Change of Transit or Circulation, Effects of Immunosuppressant Therapy
    View official trial listing →
  • Completed NCT NCT01780948

    Pharmacokinetic of Everolimus and Atorvastatin Co-administration

    Not yet reported Chulalongkorn University 18 participants Est. completion 2013-01 1 site
    Other conditions: Difference of 12-hour AUC
    View official trial listing →
  • Terminated NCT NCT01797315

    Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol

    Not yet reported University Hospital of Berlin 40 participants Est. completion 2013-06
    Other conditions: Renal Transplant Patients at High-risk for Skin Cancer
    View official trial listing →
  • Withdrawn NCT NCT01807767

    Myfortic in High MELD Liver Transplantation

    Not yet reported Medical College of Wisconsin Est. completion 2015-08 1 site
    Other conditions: High Model for End-Stage Liver Disease (MELD) Score
    View official trial listing →
  • Terminated NCT NCT01814059

    Sirolimus for Eosinophil-Associated Gastrointestinal Disorders

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 4 participants Est. completion 2015-05-12 1 site
    Other conditions: Eosinophilic Gastroenteritis, Eosinophilic Esophagitis
    View official trial listing →
  • Completed NCT NCT01827384

    MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

    Not yet reported National Cancer Institute (NCI) 208 participants Est. completion 2021-10-08 8 sites
    Other conditions: Advanced Malignant Solid Neoplasm
    View official trial listing →
  • Completed NCT NCT01827943

    Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer

    Not yet reported Institut Bergonié 54 participants Est. completion 2016-12 9 sites
    Other conditions: Relapsed Bladder Cancer
    View official trial listing →
  • Terminated NCT NCT01878786

    A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

    Not yet reported, Not yet reported Matthew Cooper 25 participants Est. completion 2017-12 1 site Stand-alone
    Other conditions: Delayed Graft Function
    View official trial listing →
  • Active, not recruiting NCT NCT01885689

    Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

    Not yet reported City of Hope Medical Center 72 participants Est. completion 2026-09-21 1 site Stand-alone
    Other conditions: Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Therapy-Related Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT01887704

    Effect of Rotablator on Balloon Resistant Calcified Coronary Lesion

    Not yet reported Capital Medical University 240 participants Est. completion 2013-05 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT01895049

    Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria

    Not yet reported Helio Tedesco Silva Junior 171 participants Est. completion 2017-03-07 1 site
    Other conditions: Kidney Transplantation, Cytomegalovirus
    View official trial listing →
  • Completed NCT NCT01902160

    Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

    Not yet reported National Cancer Institute (NCI) 3 participants 1 site
    Other conditions: Recurrent Adult Hodgkin Lymphoma
    View official trial listing →
  • Status unknown NCT NCT01927588

    Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients

    Not yet reported Fundação Pró Rim 50 participants Est. completion 2015-11
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Completed NCT NCT01938573

    Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

    Not yet reported, Not yet reported University of Washington 21 participants Est. completion 2016-08-18 2 sites Stand-alone
    Other conditions: Recurrent Bladder Carcinoma, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer
    View official trial listing →
  • Status unknown NCT NCT01954693

    A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis

    Not yet reported Cardiff University 48 participants Est. completion 2018-08-06 1 site
    Other conditions: Tuberous Sclerosis
    View official trial listing →
  • Completed NCT NCT01958190

    Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus

    Not yet reported Foundation for Liver Research 196 participants Est. completion 2021-05-20 3 sites Stand-alone
    Other conditions: Liver Disease
    View official trial listing →
  • Status unknown NCT NCT01960829

    Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study

    Not yet reported Peking University Cancer Hospital & Institute 60 participants 1 site
    Other conditions: Melanoma, TOR Serine-Threonine Kinases, Neoplasm Metastasis
    View official trial listing →
  • Terminated NCT NCT01962896

    A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors

    Not yet reported Theodore Laetsch 4 participants Est. completion 2018-01-27 3 sites Stand-alone
    Other conditions: Relapsed / Recurrent Germ Cell Tumors
    View official trial listing →
  • Completed NCT NCT01964014

    Once-a-day Immunosuppression(CISECON_a_day)

    Not yet reported Ajou University School of Medicine 160 participants Est. completion 2015-10 7 sites Stand-alone
    Other conditions: Chronic Renal Disease
    View official trial listing →
  • Completed NCT NCT02023359

    Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

    Novartis Healthcare A/S 7 participants Est. completion 2015-04 3 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02028364

    Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women

    Not yet reported Jules Bordet Institute 55 participants Est. completion 2021-08-09 5 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02048384

    A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 22 participants Est. completion 2019-09 2 sites
    Other conditions: Metastatic Pancreatic Adenocarcinoma
    View official trial listing →
  • Status unknown NCT NCT02055079

    Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease

    Not yet reported Medical University of Vienna 68 participants Est. completion 2019-12 1 site Stand-alone
    Other conditions: Polycystic Kidney, Type 1 Autosomal Dominant Disease, Polycystic Kidney, Type 2 Autosomal Dominant Disease
    View official trial listing →
  • Active, not recruiting NCT NCT02057133

    A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

    Not yet reported Eli Lilly and Company 198 participants Est. completion 2026-12 13 sites
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT02064608

    Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer

    Not yet reported Cambridge University Hospitals NHS Foundation Trust 23 participants Est. completion 2018-06 1 site
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT02071862

    Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

    Not yet reported Calithera Biosciences, Inc 210 participants Est. completion 2019-03 13 sites
    Other conditions: Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Mesothelioma, Fumarate Hydratase (FH)-Deficient Tumors, Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST), Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors, Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations, Tumors Harboring Amplifications in the cMyc Gene
    View official trial listing →
  • Completed NCT NCT02073565

    HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt

    Not yet reported OrbusNeich 572 participants Est. completion 2021-12 50 sites Stand-alone
    Other conditions: Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
    View official trial listing →
  • Status unknown NCT NCT02076516

    Pilot Evaluation Of CORACTO® (THE PILOT-SECRET TRIAL)

    Not yet reported Alvimedica 100 participants Est. completion 2015-05 5 sites
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT02109744

    Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients

    Not yet reported, Not yet reported University of Rochester 27 participants Est. completion 2022-01-01 1 site
    Other conditions: Acute Myelogenous Leukemia
    View official trial listing →
  • Status unknown NCT NCT02109913

    Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane

    Not yet reported Amsterdam UMC, location VUmc 175 participants Est. completion 2021-01 28 sites
    Other conditions: Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02113800

    Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

    Not yet reported AIO-Studien-gGmbH 40 participants Est. completion 2020-04 1 site
    Other conditions: Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3, Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3, Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
    View official trial listing →
  • Withdrawn NCT NCT02126527

    Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer

    Not yet reported Mayo Clinic 1 site Stand-alone
    Other conditions: Recurrent Non-small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT02134899

    The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients

    Not yet reported Assistance Publique - Hôpitaux de Paris 3 participants Est. completion 2017-11-11 1 site
    Other conditions: Autosomal Dominant Polycystic Kidney Disease
    View official trial listing →
  • Completed NCT NCT02184416

    Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting

    Pfizer 554 participants Est. completion 2022-09-30 110 sites
    Other conditions: Metastatic Renal Cell Carcinoma (mRCC)
    View official trial listing →
  • Completed NCT NCT02198300

    DES Versus BiOSS LIM - POLBOS II Study

    Not yet reported Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland 202 participants Est. completion 2015-03 1 site
    Cardiovascular disease
    View official trial listing →
  • Status unknown NCT NCT02208791

    Effects of the Quadruple Immunosuppression on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Kidney Transplant

    Not yet reported University of Sao Paulo General Hospital 45 participants Est. completion 2017-07 1 site Stand-alone
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT02228681

    Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

    Not yet reported GOG Foundation 74 participants Est. completion 2024-08-22 26 sites
    Other conditions: Advanced, Persistent, or Recurrent Endometrial Cancer
    View official trial listing →
  • Completed NCT NCT02241564

    Malignancies in Transplanted Patients

    Uppsala University 95 participants Est. completion 2017-06 1 site
    Other conditions: Neoplasms
    View official trial listing →
  • Completed NCT NCT02263313

    EGO-COMBO Clinical End-point Extension Study Beyond 36 Months

    The University of Hong Kong 59 participants Est. completion 2014-09 1 site
    Other conditions: Coronary Restenosis
    View official trial listing →
  • Status unknown NCT NCT02294006

    Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs

    Not yet reported Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 26 participants Est. completion 2021-10 1 site
    Other conditions: Well Differentiated Pancreatic Endocrine Tumor
    View official trial listing →
  • Terminated NCT NCT02306135

    Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer

    Dartmouth-Hitchcock Medical Center 2 participants Est. completion 2016-03 1 site
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT02343718

    Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours

    Not yet reported Canadian Cancer Trials Group 7 participants Est. completion 2019-01-16 6 sites
    Other conditions: Recurrent Lymphoma, Refractory Lymphoma, Solid Tumours, Central Nervous System
    View official trial listing →
  • Status unknown NCT NCT02360709

    Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Artery Lesions

    CID S.p.A. 800 participants Est. completion 2021-04 1 site
    Cardiovascular disease
    View official trial listing →
  • Terminated NCT NCT02372227

    A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

    Not yet reported Verastem, Inc. 21 participants Est. completion 2015-10 4 sites
    Other conditions: Relapsed Malignant Mesothelioma
    View official trial listing →
  • Completed NCT NCT02385279

    Study Comparing the MiStent SES Versus the XIENCE EES Stent

    Not yet reported ECRI bv 1398 participants Est. completion 2021-02-04 20 sites Stand-alone
    Other conditions: Coronary Stenosis
    View official trial listing →
  • Completed NCT NCT02389946

    Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

    Not yet reported Biotronik, Inc. 1334 participants Est. completion 2021-03 92 sites Stand-alone
    Cardiovascular disease Other conditions: Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease, Acute Coronary Syndrome, Angina Pectoris
    View official trial listing →
  • Completed NCT NCT02407054

    A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

    Not yet reported Eli Lilly and Company 142 participants Est. completion 2020-04-16 36 sites
    Other conditions: Prostate Cancer Metastatic
    View official trial listing →
  • Completed NCT NCT02423915

    Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention

    Not yet reported M.D. Anderson Cancer Center 5 participants Est. completion 2020-10-06 1 site Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT02441543

    Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus

    Istituto Clinico Humanitas 45 participants Est. completion 2018-05 1 site
    Other conditions: SOLID TUMOR
    View official trial listing →
  • Completed NCT NCT02484664

    COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC

    Not yet reported Brigham and Women's Hospital 12 participants Est. completion 2018-11-19 1 site
    Other conditions: Lymphangioleiomyomatosis (LAM)
    View official trial listing →
  • Status unknown NCT NCT02493465

    Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study

    Not yet reported Instituto de Urologia e Nefrologia 50 participants Est. completion 2017-07 1 site
    Other conditions: Left Ventricular Hypertrophy
    View official trial listing →
  • Completed NCT NCT02494570

    A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa

    Not yet reported Aadi Bioscience, Inc. 34 participants Est. completion 2022-04 9 sites Stand-alone
    Other conditions: Malignant PEComa
    View official trial listing →
  • Completed NCT NCT02512003

    Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I)

    Not yet reported REVA Medical, Inc. 7 participants Est. completion 2020-04 2 sites
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT02514824

    MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 9 participants Est. completion 2017-06 1 site
    Other conditions: Merkel Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT02517918

    Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma

    Not yet reported Institut Bergonié 23 participants Est. completion 2021-11-16 3 sites Stand-alone
    Obstructive sleep apnea Other conditions: Solid Tumor
    View official trial listing →
  • Completed NCT NCT02531932

    Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

    Not yet reported Amy Tiersten 64 participants Est. completion 2024-10-19 3 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02567435

    Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

    Not yet reported National Cancer Institute (NCI) 325 participants Est. completion 2026-10-27 382 sites
    Obstructive sleep apnea
    View official trial listing →
  • Completed NCT NCT02646319

    Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

    Not yet reported Mayo Clinic 2 participants Est. completion 2018-04-24 2 sites
    Other conditions: Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma, Malignant Uterine Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Malignant Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage III Bladder Cancer, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Breast Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Breast Cancer, Stage IIIC Ovarian Cancer, Stage IV Breast Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IVA Bladder Cancer, Stage IVA Cervical Cancer, Stage IVB Bladder Cancer, Stage IVB Cervical Cancer
    View official trial listing →
  • Completed NCT NCT02669511

    PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

    Not yet reported PIQUR Therapeutics AG 21 participants Est. completion 2018-01-12
    Other conditions: Primary Central Nervous System Lymphoma
    View official trial listing →
  • Completed NCT NCT02688868

    Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 )

    Not yet reported Shanghai MicroPort Medical (Group) Co., Ltd. 38 participants Est. completion 2020-12 1 site
    Other conditions: Coronary Heart Disease
    View official trial listing →
  • Status unknown NCT NCT02698839

    A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)

    Not yet reported Sino Medical Sciences Technology Inc. 539 participants Est. completion 2025-12 1 site
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT02711826

    Treg Therapy in Subclinical Inflammation in Kidney Transplantation

    Not yet reported, Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 32 participants Est. completion 2023-08-04 6 sites
    Other conditions: Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant, Living Kidney Donor
    View official trial listing →
  • Completed NCT NCT02724332

    Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC

    Not yet reported Eastern Hepatobiliary Surgery Hospital 300 participants Est. completion 2015-12 1 site
    Other conditions: Hepatocellular Carcinoma, Rapamycin
    View official trial listing →
  • Status unknown NCT NCT02730923

    Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)

    Not yet reported, Not yet reported Centre Leon Berard 72 participants Est. completion 2024-12 12 sites
    Other conditions: Endometrial Carcinoma, Metastatic Carcinoma, Hormone Receptor Positive Tumor
    View official trial listing →
  • Completed NCT NCT02732119

    Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

    Not yet reported, Not yet reported Novartis Pharmaceuticals 104 participants Est. completion 2020-02-25 25 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02812940

    Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT

    Not yet reported University of Cologne 19 participants Est. completion 2020-12 1 site
    Other conditions: Graft-versus-Host Disease
    View official trial listing →
  • Completed NCT NCT02821026

    Omental Islet Transplant

    Not yet reported, Not yet reported University of Alberta 4 participants Est. completion 2019-11-13 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT02821507

    Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma

    Not yet reported Leiden University Medical Center 70 participants Est. completion 2021-12 7 sites Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Withdrawn NCT NCT02833506

    Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Not yet reported Roswell Park Cancer Institute Est. completion 2019-08-15 1 site Stand-alone
    Other conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
    View official trial listing →
  • Status unknown NCT NCT02853994

    Safety and Efficacy of the DEVOIR Sirolimus-Coated Coronary Balloon in the Real-world Clinical Practice

    MINVASYS 500 participants Est. completion 2018-09
    Other conditions: CAD
    View official trial listing →
  • Completed NCT NCT02869087

    The DESappear Study: Drug Eluting Scaffold

    Not yet reported Elixir Medical Corporation 21 participants Est. completion 2021-04-30 11 sites Stand-alone
    Other conditions: Peripheral Vascular Disease
    View official trial listing →
  • Completed NCT NCT02890160

    A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II

    Not yet reported Shanghai MicroPort Medical (Group) Co., Ltd. 430 participants Est. completion 2024-10-03 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT02905214

    Coroflex ISAR 2000 Extended Registry (ISAR2000 Extended)

    B. Braun Melsungen AG 4369 participants Est. completion 2021-12 3 sites
    Cardiovascular disease
    View official trial listing →
  • Status unknown NCT NCT02908035

    Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

    Not yet reported Mercator MedSystems, Inc. 100 participants Est. completion 2021-09 8 sites
    Other conditions: Chronic Limb Ischemia
    View official trial listing →
  • Completed NCT NCT02954198

    Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients

    Not yet reported Medical University of South Carolina 40 participants Est. completion 2018-12-27 1 site
    Other conditions: Immunosuppression
    View official trial listing →
  • Completed NCT NCT02959918

    Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

    Not yet reported Selecta Biosciences, Inc. 152 participants Est. completion 2019-01 13 sites
    Other conditions: Gout Chronic, Hyperuricemia
    View official trial listing →
  • Completed NCT NCT02960997

    Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

    Not yet reported Stanford University 8 participants Est. completion 2021-12-01 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Weber-Cockayne Syndrome
    View official trial listing →
  • Completed NCT NCT02970630

    Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study

    Not yet reported Chiesi Farmaceutici S.p.A. 28 participants Est. completion 2018-02-22 6 sites
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT02973204

    Circulating Tumor Cells and Tumor DNA in HCC and NET

    University of Aarhus 167 participants Est. completion 2020-01-08 1 site
    Other conditions: Carcinoma, Hepatocellular, Neuroendocrine Tumors
    View official trial listing →
  • Terminated NCT NCT02987959

    Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

    Not yet reported Fox Chase Cancer Center 6 participants Est. completion 2020-07-24 1 site
    Other conditions: Soft-tissue Sarcoma
    View official trial listing →
  • Terminated NCT NCT03014297

    Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

    Not yet reported Lowell Anthony, MD 17 participants Est. completion 2018-11-16 1 site
    Other conditions: Neuroendocrine Tumors, Everolimus
    View official trial listing →
  • Status unknown NCT NCT03040934

    Firehawk™ Coronary Stent System in the Treatment of Coronary Chronic Total Occlusion Lesion(s)

    Not yet reported Shanghai MicroPort Medical (Group) Co., Ltd. 196 participants Est. completion 2023-10 1 site
    Other conditions: Drug-Eluting Stents, Percutaneous Coronary Intervention, Tomography, Optical Coherence
    View official trial listing →
  • Completed NCT NCT03085823

    The All-comers Sirolimus-coated Balloon European Registry

    Fatebenefratelli and Ophthalmic Hospital 2123 participants Est. completion 2022-01 1 site
    Other conditions: Percutaneous Coronary Intervention, Angioplasty, Balloon, Coronary, Coronary Angioplasty, Transluminal Balloon, Arteriosclerosis, Coronary
    View official trial listing →
  • Status unknown NCT NCT03089450

    To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent

    Not yet reported CGBio Inc. 112 participants Est. completion 2018-06 1 site Stand-alone
    Cardiovascular disease Other conditions: Ischemic Heart Disease, Stable Angina, Unstable Angina, NSTEMI - Non-ST Segment Elevation MI
    View official trial listing →
  • Completed NCT NCT03095703

    Sirolimus and Familial Adenomatous Polyposis (FAP)

    Not yet reported Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 4 participants Est. completion 2018-12-10 1 site Stand-alone
    Other conditions: Adenomatous Polyposis Coli
    View official trial listing →
  • Completed NCT NCT03103893

    Novel Compositions for Treating or Preventing Dermal Disorders

    Not yet reported, Not yet reported Drexel University 36 participants Est. completion 2017-11-30 1 site
    Other conditions: Dermal Atrophy
    View official trial listing →
  • Completed NCT NCT03112603

    A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

    Not yet reported Incyte Corporation 330 participants Est. completion 2022-12-15 191 sites
    Other conditions: Graft-versus-host Disease (GVHD)
    View official trial listing →
  • Completed NCT NCT03140449

    Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis

    Not yet reported National Taiwan University Hospital 52 participants Est. completion 2017-04-25
    Other conditions: Facial Angiofibroma
    View official trial listing →
  • Active, not recruiting NCT NCT03192397

    Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

    Not yet reported, Not yet reported Roswell Park Cancer Institute 35 participants Est. completion 2027-05-21 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Chronic Myelomonocytic Leukemia in Remission, Graft Versus Host Disease, Hodgkin Lymphoma, Minimal Residual Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Severe Aplastic Anemia, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT03198949

    A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)

    Not yet reported Yonsei University 23 participants Est. completion 2020-09-11 1 site
    Other conditions: Epilepsy and Focal Cortical Dysplasia II
    View official trial listing →
  • Terminated NCT NCT03203525

    Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

    Not yet reported M.D. Anderson Cancer Center 38 participants Est. completion 2026-07-22 1 site
    Other conditions: Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Neoplasm
    View official trial listing →
  • Active, not recruiting NCT NCT03216733

    SORT OUT X - Combo Stent Versus ORSIRO Stent

    Not yet reported Aarhus University Hospital Skejby 3148 participants Est. completion 2028-12-31 4 sites
    Cardiovascular disease Other conditions: Coronary Heart Disease, Angina Pectoris
    View official trial listing →
  • Status unknown NCT NCT03225417

    Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

    Not yet reported, Not yet reported Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 142 participants Est. completion 2024-12-31 8 sites Stand-alone
    Other conditions: Hematopoietic Stem Cell Transplantation, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03234348

    MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction

    Not yet reported Hospital Clinic of Barcelona 151 participants Est. completion 2019-10-31 11 sites Stand-alone
    Cardiovascular disease Other conditions: Acute Coronary Syndrome, Stent
    View official trial listing →
  • Completed NCT NCT03245151

    Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

    Not yet reported, Not yet reported Eisai Inc. 64 participants Est. completion 2022-09-30 50 sites
    Other conditions: Recurrent and Refractory Solid Tumors
    View official trial listing →
  • Terminated NCT NCT03246906

    Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

    Not yet reported Fred Hutchinson Cancer Center 150 participants Est. completion 2025-05-03 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Hematologic and Lymphocytic Disorder, Blastic Plasmacytoid Dendritic Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT03256864

    Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient

    Not yet reported Chang Gung Memorial Hospital 10 participants Est. completion 2020-05-30 1 site
    Other conditions: Liver Transplantation
    View official trial listing →
  • Completed NCT NCT03304678

    Discovery of Sirolimus Sensitive Biomarkers in Blood

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 33 participants Est. completion 2025-03-14 1 site
    Other conditions: Lymphangioleiomyomatosis
    View official trial listing →
  • Active, not recruiting NCT NCT03334617

    Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

    Not yet reported AstraZeneca 528 participants Est. completion 2026-09-11 45 sites
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT03363763

    Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

    Not yet reported Aucta Pharmaceuticals, Inc 24 participants Est. completion 2023-03-24 8 sites
    Other conditions: Angiofibroma of Face, Tuberous Sclerosis
    View official trial listing →
  • Completed NCT NCT03383380

    Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome

    Not yet reported, Not yet reported Children's Hospital of Fudan University 30 participants Est. completion 2023-11-30 2 sites
    Other conditions: Activated PI3K-delta Syndrome, Immunodeficiency Primary
    View official trial listing →
  • Completed NCT NCT03434704

    Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole

    Not yet reported Ciceri Fabio 10 participants Est. completion 2019-10-13 1 site Stand-alone
    Other conditions: Transplant-Related Hematologic Malignancy, Leukemia, Acute, Myelodysplastic Syndromes, Graft Vs Host Disease, Fungal Infection
    View official trial listing →
  • Completed NCT NCT03439462

    Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

    Not yet reported, Not yet reported Aadi Bioscience, Inc. 60 participants Est. completion 2022-08-26 6 sites Stand-alone
    Other conditions: Colorectal Cancer Metastatic
    View official trial listing →
  • Completed NCT NCT03471234

    Latin America Real World Study With Inspiron Drug Eluting Stent - INSPIRON LATITUDE

    Scitech Produtos Medicos SA 299 participants Est. completion 2022-08-02 2 sites
    Cardiovascular disease
    View official trial listing →
  • Terminated NCT NCT03484234

    Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-VII: Sirolimus-eluting (Ultimaster) vs. Everolimus-Eluting Stents (Xience)

    Not yet reported Seung-Jung Park 36 participants Est. completion 2019-09-06 2 sites
    Cardiovascular disease Other conditions: Coronary Stenosis
    View official trial listing →
  • Status unknown NCT NCT03500367

    Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis

    Not yet reported Peking Union Medical College Hospital 25 participants Est. completion 2022-12-31 1 site
    Other conditions: Uterine Fibroids
    View official trial listing →
  • Status unknown NCT NCT03500848

    Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation

    Not yet reported, Not yet reported Southern Medical University, China 130 participants Est. completion 2023-05-31 3 sites Stand-alone
    Other conditions: Liver Transplantation
    View official trial listing →
  • Completed NCT NCT03507205

    Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents

    Seoul National University Hospital 17286 participants Est. completion 2017-11-30 37 sites
    Cardiovascular disease
    View official trial listing →
  • Status unknown NCT NCT03509532

    DRUG ELUTING STENT FOR DIABETIC PATIENTS IN CORONARY ARTERY DISEASE TREATMENT

    I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio 5000 participants Est. completion 2022-01 1 site
    Cardiovascular disease
    View official trial listing →
  • Status unknown NCT NCT03616132

    A First-in-Man Study to Evaluate the Feasibility and Safety of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System

    Not yet reported Lifetech Scientific (Shenzhen) Co., Ltd. 15 participants Est. completion 2023-03-30 2 sites Stand-alone
    Other conditions: Single Coronary Vessel Disease
    View official trial listing →
  • Completed NCT NCT03634020

    DynamX Sirolimus Study Sirolimus Eluting Coronary Bioadaptor System

    Not yet reported Elixir Medical Corporation 44 participants Est. completion 2021-03-08 7 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Withdrawn NCT NCT03657420

    Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

    Not yet reported Massachusetts General Hospital Est. completion 2024-09-30 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03688191

    Study of Sirolimus in CTD-TP in China

    Not yet reported Peking Union Medical College Hospital 20 participants Est. completion 2019-09-30 1 site Stand-alone
    Other conditions: Connective Tissue Diseases, Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT03696355

    Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas

    Not yet reported St. Jude Children's Research Hospital 27 participants Est. completion 2022-09-04 1 site
    Other conditions: Brain and Central Nervous System Tumors
    View official trial listing →
  • Terminated NCT NCT03740100

    Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations

    Not yet reported M.D. Anderson Cancer Center 8 participants Est. completion 2020-12-09 1 site
    Other conditions: HNSCC
    View official trial listing →
  • Completed NCT NCT03871361

    Abatacept in Patients With Birdshot HLA A29 Uveitis

    Not yet reported Universitaire Ziekenhuizen KU Leuven 15 participants Est. completion 2023-12-01 1 site Stand-alone
    Other conditions: Eye Diseases, Uveitis
    View official trial listing →
  • Status unknown NCT NCT03901001

    Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza

    Not yet reported Chinese University of Hong Kong 160 participants Est. completion 2025-12-31 1 site
    Other conditions: Influenza
    View official trial listing →
  • Completed NCT NCT03908450

    Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter

    Not yet reported InnoRa GmbH 70 participants Est. completion 2023-07-31 4 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Active, not recruiting NCT NCT03910452

    Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 4 participants Est. completion 2034-06-15 1 site Stand-alone
    Other conditions: Chronic Granulomatous Disease
    View official trial listing →
  • Status unknown NCT NCT03916432

    HELIOS China Registry: Evaluation of the HELIOS Stent in a 'Real-World' Patient Population

    Not yet reported Xijing Hospital 3000 participants Est. completion 2025-12-01 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Terminated NCT NCT03942601

    Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

    Not yet reported Mercator MedSystems, Inc. 10 participants Est. completion 2021-04-30 11 sites
    Other conditions: Peripheral Arterial Disease
    View official trial listing →
  • Active, not recruiting NCT NCT03950609

    Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

    Not yet reported M.D. Anderson Cancer Center 36 participants Est. completion 2028-03-30 1 site
    Other conditions: Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1, Neuroendocrine Neoplasm, Unresectable Carcinoid Tumor
    View official trial listing →
  • Active, not recruiting NCT NCT03952273

    Sort Out XI - Combo Stent Versus BioMatrix Alpha Stent

    Not yet reported Phillip Freeman 3141 participants Est. completion 2030-11-30 2 sites
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT03972462

    NPC-12G Gel 0.2% Sirolimus PK Bridging Study

    Not yet reported Nobelpharma 12 participants Est. completion 2019-06-17 1 site Stand-alone
    Other conditions: Bioavailability Study
    View official trial listing →
  • Active, not recruiting NCT NCT03983850

    Optimizing PTCy Dose and Timing

    Not yet reported, Not yet reported National Cancer Institute (NCI) 105 participants Est. completion 2026-10-26 1 site Stand-alone
    Other conditions: Graft Versus Host Disease, Hematologic Neoplasms
    View official trial listing →
  • Status unknown NCT NCT04014595

    PREPARE-CALC-COMBO: Severely Calcified Coronary Lesions Prepared With Rotational Atherectomy and Modified Balloons

    Segeberger Kliniken GmbH 100 participants Est. completion 2025-07-31 1 site
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT04107298

    Safety and Feasibility of Surmodics SUNDANCE™ Drug Coated Balloon

    Not yet reported SurModics, Inc. 35 participants Est. completion 2024-01-30 8 sites Stand-alone
    Other conditions: Peripheral Arterial Disease, Critical Lower Limb Ischemia
    View official trial listing →
  • Active, not recruiting NCT NCT04177004

    Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

    Not yet reported City of Hope Medical Center 52 participants Est. completion 2026-10-27 1 site Stand-alone
    Other conditions: Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT04200911

    Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway

    Not yet reported The University of Texas Health Science Center at San Antonio 10 participants Est. completion 2022-01-13 1 site Stand-alone
    Other conditions: Cognitive Impairment, Mild, Alzheimer Disease
    View official trial listing →
  • Status unknown NCT NCT04236609

    Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

    Not yet reported Concept Medical Inc. 3050 participants Est. completion 2024-09-30 90 sites
    Cardiovascular disease Other conditions: Diabetes, Acute Coronary Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT04238546

    Major Adverse Limb Events in Patients With Femoro-popliteal and Below-the-knee Peripheral Arterial Disease Treated With Either Sirolimus-coated Balloon or Standard Uncoated Balloon Angioplasty

    Not yet reported Nils Kucher 1200 participants Est. completion 2029-12-31 2 sites Stand-alone
    Other conditions: Peripheral Arterial Disease
    View official trial listing →
  • Status unknown NCT NCT04247750

    Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP)

    Not yet reported Università degli Studi di Ferrara 45 participants Est. completion 2022-04-30 4 sites Stand-alone
    Other conditions: Beta-Thalassemia
    View official trial listing →
  • Terminated NCT NCT04258423

    Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

    Not yet reported Indiana University 4 participants Est. completion 2020-06-27 1 site
    Other conditions: Kidney Failure
    View official trial listing →
  • Completed NCT NCT04327609

    SAVE Trial - Use of the Selution Sirolimus Eluting Balloon for Dysfunctional AV accEss Treatment Indications

    Not yet reported M.A. Med Alliance S.A. 84 participants Est. completion 2025-07-23 3 sites Stand-alone
    Other conditions: AV Fistula
    View official trial listing →
  • Active, not recruiting NCT NCT04375813

    Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

    Not yet reported Robert Svatek 166 participants Est. completion 2027-07 2 sites
    Other conditions: Non-muscle Invasive Bladder Cancer
    View official trial listing →
  • Status unknown NCT NCT04409691

    SCMC Trial on KHE With KMP (V.2020)

    Not yet reported Shanghai Children's Medical Center 20 participants Est. completion 2023-06-30 1 site Stand-alone
    Other conditions: Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP)
    View official trial listing →
  • Completed NCT NCT04470804

    Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA

    Not yet reported Bing Han 56 participants Est. completion 2022-07-31 1 site Stand-alone
    Other conditions: Pure Red Cell Aplasia, Acquired
    View official trial listing →
  • Completed NCT NCT04473911

    Haplo Peripheral Blood Sct In GVHD Prevention

    Not yet reported Zachariah Michael DeFilipp 25 participants Est. completion 2024-08-19 1 site Stand-alone
    Other conditions: GVHD, AML, ALL, MDS, MPN, CMML, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Blood Stem Cell Transplant Failure, Graft Vs Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Myelomonocytic Leukemia, Chemosensitive Hodgkin Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT04482712

    Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS

    Not yet reported, Not yet reported The University of Texas Health Science Center at San Antonio Est. completion 2023-01 2 sites
    Other conditions: Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Respiratory Failure, Sars-CoV2
    View official trial listing →
  • Status unknown NCT NCT04570345

    3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI

    Not yet reported Dong-A University 1002 participants Est. completion 2022-08 1 site
    Cardiovascular disease
    View official trial listing →
  • Active, not recruiting NCT NCT04629495

    Rapamycin - Effects on Alzheimer's and Cognitive Health

    Not yet reported The University of Texas Health Science Center at San Antonio 40 participants Est. completion 2027-03-05 1 site
    Other conditions: Mild Cognitive Impairment, Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT04775173

    Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.

    Not yet reported West China Hospital 79 participants Est. completion 2023-08-10 1 site Stand-alone
    Other conditions: Kaposiform Hemangioendothelioma
    View official trial listing →
  • Completed NCT NCT04818632

    AZD9833 China PK Study

    Not yet reported AstraZeneca 28 participants Est. completion 2023-09-07 4 sites
    Other conditions: ER+, HER2-, Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04849533

    Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)

    Not yet reported University of Cincinnati 120 participants Est. completion 2024-07 2 sites
    Other conditions: Kidney Transplant Rejection
    View official trial listing →
  • Terminated NCT NCT04895748

    DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

    Not yet reported Novartis Pharmaceuticals 40 participants Est. completion 2026-02-13 11 sites
    Other conditions: Carcinoma, Renal Cell
    View official trial listing →
  • Status unknown NCT NCT05032131

    Cell Therapy for IBM by Muscle Injection of ADSVF

    Not yet reported Assistance Publique - Hôpitaux de Paris 32 participants Est. completion 2024-04 1 site Stand-alone
    Other conditions: Inclusion Body Myositis
    View official trial listing →
  • Completed NCT NCT05050149

    Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations

    Not yet reported Palvella Therapeutics, Inc. 12 participants Est. completion 2022-12-15 7 sites
    Other conditions: Microcystic Lymphatic Malformation
    View official trial listing →
  • Withdrawn NCT NCT05079360

    Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

    Not yet reported Veru Inc. Est. completion 2024-05-26 26 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05132166

    A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease

    Not yet reported University Health Network, Toronto 50 participants Est. completion 2026-04-26 1 site
    Other conditions: Graft Vs Host Disease
    View official trial listing →
  • Completed NCT NCT05153668

    Everolimus Trial in Laryngotracheal Stenosis

    Not yet reported Johns Hopkins University 8 participants Est. completion 2025-10-23 1 site
    Other conditions: Idiopathic Subglottic Tracheal Stenosis
    View official trial listing →
  • Completed NCT NCT05180708

    A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

    Not yet reported Palvella Therapeutics, Inc. 87 participants Est. completion 2023-06-30 8 sites
    Other conditions: Pachyonychia Congenita
    View official trial listing →
  • Active, not recruiting NCT NCT05193565

    Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients

    Not yet reported Chong Kun Dang Pharmaceutical 206 participants Est. completion 2026-11 1 site Stand-alone
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Status unknown NCT NCT05267548

    Investigating the Safety and Clinical Performance of Seven iVascular Devices for Endovascular Intervention in the Popliteal and/or Infrapopliteal Arteries

    iVascular S.L.U. 143 participants Est. completion 2025-05 8 sites
    Other conditions: Peripheral Arterial Disease Below The Knee
    View official trial listing →
  • Completed NCT NCT05269849

    Sirolimus for Nosebleeds in HHT

    Not yet reported Unity Health Toronto 10 participants Est. completion 2024-12-02 1 site Stand-alone
    Other conditions: Hereditary Hemorrhagic Telangiectasia, Nosebleeds, Epistaxis
    View official trial listing →
  • Active, not recruiting NCT NCT05293964

    Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

    Not yet reported Jiangsu Simcere Pharmaceutical Co., Ltd. 214 participants Est. completion 2025-09-08 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT05298358

    RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1 participants Est. completion 2024-11-21 1 site Stand-alone
    Other conditions: Systemic Sclerosis
    View official trial listing →
  • Withdrawn NCT NCT05417893

    Non-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions

    Not yet reported Meril Life Sciences Pvt. Ltd. Est. completion 2023-09-23
    Cardiovascular disease
    View official trial listing →
  • Active, not recruiting NCT NCT05467397

    Feasibility of [11C]Acetate-PET in LAM and TSC

    Not yet reported, Not yet reported Brigham and Women's Hospital 7 participants Est. completion 2026-06-30 1 site
    Other conditions: Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
    View official trial listing →
  • Completed NCT NCT05495425

    Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC

    Not yet reported Nobelpharma 43 participants Est. completion 2024-10-30 5 sites Stand-alone
    Other conditions: Tuberous Sclerosis Complex
    View official trial listing →
  • Status unknown NCT NCT05613166

    Adjunctive Everolimus Treatment of Refractory Epilepsy

    Not yet reported National Institute on Drug Dependence, China 108 participants Est. completion 2023-03 1 site
    Other conditions: Epilepsy
    View official trial listing →
  • Status unknown NCT NCT05616156

    The Cre8™ BTK Post Market Clinical Follow-up Study

    CID S.p.A. 50 participants Est. completion 2023-07 2 sites
    Other conditions: Peripheral Arterial Disease
    View official trial listing →
  • Status unknown NCT NCT05662618

    To Verify the Efficacy and Safety of Rapamycin Coated Peripheral Balloon Catheter in the Treatment of Femoral Popliteal Artery Disease

    Not yet reported Shanghai Bomaian Medical Technology Co., Ltd 276 participants Est. completion 2025-06-30 1 site
    Other conditions: Peripheral Arterial Disease
    View official trial listing →
  • Completed NCT NCT05677711

    Safety and Efficacy of the Ultimaster Stent

    Yonsei University 204 participants Est. completion 2025-01-03 1 site
    Cardiovascular disease Other conditions: Drug-eluting Stents
    View official trial listing →
  • Status unknown NCT NCT05703646

    Safety and Clinical Performance of the Yukon Choice PC, Yukon Chrome PC & Yukon Choice Flex Stents in Routine Practice

    Translumina GmbH 5000 participants Est. completion 2026-03-30 1 site
    Other conditions: Ischemic Heart Disease
    View official trial listing →
  • Completed NCT NCT05719883

    Evaluating the Safety and Efficacy of the Maurora® DES in ICAS

    Not yet reported Beijing Tiantan Hospital 156 participants Est. completion 2025-05-15 1 site Stand-alone
    Cardiovascular disease Other conditions: Intracranial Arteriosclerosis
    View official trial listing →
  • Not yet recruiting NCT NCT05746689

    Study of Sirolimus in IgG4-related Disease

    Not yet reported Peking University International Hospital 20 participants Est. completion 2028-12-31 Stand-alone
    Other conditions: IgG4-related Disease
    View official trial listing →
  • Terminated NCT NCT05773326

    Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG

    Not yet reported Nader Sanai 5 participants Est. completion 2025-10-16 1 site
    Other conditions: High Grade Glioma, Glioma, Glioma, Malignant, Glioblastoma
    View official trial listing →
  • Status unknown NCT NCT05801003

    Cutting Balloon Predilation Prior to Abluminus Sirolimus-eluting Stent Implantation (CUT-DRESS).

    Not yet reported Hospital Universitario La Fe 96 participants Est. completion 2025-01-01 3 sites
    Cardiovascular disease Other conditions: Percutaneous Coronary Intervention, Cutting Balloon
    View official trial listing →
  • Status unknown NCT NCT05833815

    Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

    Not yet reported, Not yet reported Banaras Hindu University 56 participants Est. completion 2024-12-30 1 site
    Other conditions: Gallbladder Cancer
    View official trial listing →
  • Status unknown NCT NCT05920512

    Combination Regimen With Sodium Valproate for Severe Hemophilia: a Single-arm, Phase 1, Pilot Trial.

    Not yet reported, Not yet reported Xue-chun Lu 10 participants Est. completion 2025-04-01 1 site Stand-alone
    Other conditions: Hemophilia
    View official trial listing →
  • Status unknown NCT NCT05954442

    Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

    Not yet reported Fudan University 203 participants Est. completion 2026-08 1 site
    Other conditions: Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation
    View official trial listing →
  • Completed NCT NCT06065345

    BRight Pharmacokinetic Study

    Not yet reported Biotronik CRC Inc. 6 participants Est. completion 2025-07-22 1 site
    Other conditions: Peripheral Artery Disease
    View official trial listing →
  • Active, not recruiting NCT NCT06075368

    Efficacy and Safety of GENOSS® SES in Patients With Acute Coronary Syndrome (GENOSS ACS)

    Genoss Co., Ltd. 757 participants Est. completion 2027-12-31 1 site
    Other conditions: Acute Coronary Syndrome, Percutaneous Coronary Intervention
    View official trial listing →
  • Terminated NCT NCT06078696

    Siplizumab for Sickle Cell Disease Transplant

    Not yet reported, Not yet reported Columbia University 1 participants Est. completion 2025-12-11 1 site Stand-alone
    Other conditions: Anemia, Sickle Cell
    View official trial listing →
  • Active, not recruiting NCT NCT06105632

    A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

    Not yet reported Pfizer 333 participants Est. completion 2028-01-21 48 sites
    Other conditions: Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06145282

    Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

    Not yet reported, Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 6 participants Est. completion 2027-11-26 1 site Stand-alone
    Other conditions: Sickle Cell Disease
    View official trial listing →
  • Status unknown NCT NCT06160739

    Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations

    Sohag University 10 participants Est. completion 2024-09-01 1 site
    Other conditions: Microcystic Lymphatic Malformation, Combined Vascular Malformation, Vascular Malformations
    View official trial listing →
  • Active, not recruiting NCT NCT06239480

    SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

    Not yet reported Palvella Therapeutics, Inc. 51 participants Est. completion 2026-07 15 sites
    Other conditions: Microcystic Lymphatic Malformation
    View official trial listing →
  • Not yet recruiting NCT NCT06300268

    Advapro Coronary Stent System in Coronary Artery Diseased Patients.

    Not yet reported Advanced MedTech Solutions Pvt. Ltd. 120 participants Est. completion 2026-12
    Cardiovascular disease Other conditions: De Novo Stenosis Lesion, Coronary Stent Implantation
    View official trial listing →
  • Status unknown NCT NCT06317298

    Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

    Not yet reported Peking University First Hospital 36 participants Est. completion 2025-12-01 1 site
    Other conditions: Renal Cell Carcinoma, Clear Cell, Somatic
    View official trial listing →
  • Completed NCT NCT06341998

    Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children

    Not yet reported, Not yet reported Shandong First Medical University 32 participants Est. completion 2024-02-01 1 site Stand-alone
    Other conditions: Germ Cell Tumor, Yolk Sac Tumor
    View official trial listing →
  • Status unknown NCT NCT06345209

    Efficacy and Safety of Sirolimus-coated Coronary Balloon Dilatation Catheter for Coronary Small Vessels

    Not yet reported BrosMed Medical Co., Ltd 236 participants Est. completion 2025-12 Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT06940895

    Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans

    Not yet reported Narrows Institute for Biomedical Research 5 participants Est. completion 2025-07-18 1 site Stand-alone
    Other conditions: Acanthosis Nigricans
    View official trial listing →
  • Not yet recruiting NCT NCT06941142

    A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

    Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 382 participants Est. completion 2028-06 Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT06981845

    Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis

    Not yet reported China National Center for Cardiovascular Diseases 52 participants Est. completion 2028-06-01 Stand-alone
    Cardiovascular disease Other conditions: In-stent Restenosis Lesion
    View official trial listing →
  • Active, not recruiting NCT NCT07054320

    Rapamycin and Infection-related Illness

    Hoskinson Health and Wellness Clinic 15 participants Est. completion 2026-06 1 site
    Other conditions: Infectious Diseases
    View official trial listing →
  • Active, not recruiting NCT NCT07058974

    A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation

    Not yet reported Icahn School of Medicine at Mount Sinai 20 participants Est. completion 2027-06-15 1 site Stand-alone
    Other conditions: Smokers, Former Smokers
    View official trial listing →
  • Active, not recruiting NCT NCT07151157

    Therapeutic Value of Sirolimus in Refractory Adult-Onset Still's Disease

    Not yet reported Ruijin Hospital 3 participants Est. completion 2026-08-30 1 site Stand-alone
    Other conditions: Adult-Onset Still's Disease
    View official trial listing →
  • Withdrawn NCT NCT07329088

    Isoleucine Addition Treatment Effects in a Controlled Diet Study

    Not yet reported Jean L. Fry Est. completion 2029-01-31 1 site
    PrediabetesMetabolic syndrome Other conditions: Obesity & Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT07354620

    A Pilot Study on Reverse Aging (The REVERSE Study)

    Not yet reported The Christ Hospital 52 participants Est. completion 2026-05 1 site
    Other conditions: Aging
    View official trial listing →
  • Not yet recruiting NCT NCT07436611

    Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains

    Not yet reported AFT Pharmaceuticals, Ltd. 30 participants Est. completion 2027-10 2 sites
    Other conditions: Port Wine Stains
    View official trial listing →
  • Active, not recruiting NCT NCT07475546

    Combination Gerotherapeutic Interventions for Healthspan Improvement

    Not yet reported AgelessRx 30 participants Est. completion 2026-04 1 site
    Other conditions: Healthspan Improvement, Aging, Longevity
    View official trial listing →
  • Not yet recruiting NCT NCT07542314

    Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting

    Not yet reported Sarepta Therapeutics, Inc. 20 participants Est. completion 2027-08-31 1 site
    Other conditions: Duchenne Muscular Dystrophy
    View official trial listing →
  • Not yet recruiting NCT NCT07566091

    Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers

    Not yet reported Jung-min Ahn 2034 participants Est. completion 2028-06-15 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Not yet recruiting NCT NCT07634120

    Vertebrobasilar Dolichoectasia Treatment With Sirolimus

    Not yet reported Huashan Hospital 12 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Vertebrobasilar Dolichoectasia
    View official trial listing →
  • Not yet recruiting NCT NCT07667413

    Topical TOR-582 Treatment of Epistaxis in HHT

    Not yet reported Columbia University 27 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
    View official trial listing →
  • Available NCT NCT07689942

    Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis

    Biodexa Pharmaceuticals
    Other conditions: Familial Adenomatous Polyposis (FAP)
    View official trial listing →
  • Not yet recruiting NCT NCT07728175

    Effects of Sirolimus on Asymptomatic ApoE4 Carriers

    Not yet reported University of Missouri-Columbia 225 participants Est. completion 2028-07-07 1 site
    Other conditions: Genetic Predisposition to Disease, Healthy Volunteer, APOE-4 Positive
    View official trial listing →
  • Not yet recruiting NCT NCT07735546

    A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma

    Not yet reported Umoja Biopharma 100 participants Est. completion 2029-12-31 Stand-alone
    Other conditions: Multiple Myeloma in Relapse, Multiple Myeloma (MM)
    View official trial listing →
  • Not yet recruiting NCT NCT07813533

    A Pilot Study to Examine the Efficacy and Tolerability of Sirolimus on Epidermal Nevi Lesions in Patients 6 Years Old and Above.

    Not yet reported Northwestern University 14 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Epidermal Nevi
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.